

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Claim 37(Previously presented): A method in accordance with claim 29, wherein said method the progression of viral dissemination via a CMV-infected leukocyte is slowed.

Claim 38 (Previously presented): A method in accordance with claim 5, wherein said method the progression of viral dissemination via a CMV-infected leukocyte is slowed.

Claim 39 (Previously presented): A method of claim 29, wherein the chemokine is fractalkine.

Claim 40 (Previously presented): A method of claim 5, wherein the chemokine is fractalkine.

REMARKS/ARGUMENTS

Claims 5, 7-13, and 29-40 were previously pending and presented for examination. Claims 5, 8, 29, and 32 are amended herein. Claims 7 and 30 are canceled without prejudice. After entry of the amendments, claims 5, 8-13, 29, and 31-40 will be pending.

Claims 5 and 29 stand rejected for an alleged want of enablement.

Claims 5, 7-13, and 29-40 stand rejected for an alleged lack of nonobviousness.

Applicants respectfully respond to the above rejections below.

Amendments to the Claims

Base claims 5 and 29 have been amended to recite the compound subject matter of their canceled dependent claims 7 and 30, respectively. In addition, the recital of a "small organic compound having a molecular weight of less than 800 daltons" has been deleted. Support for the above amendments is found *inter alia* in the previous versions of claims 5, 7, 29, and 30.

Claims 8, 13 and 32 were amended to correct their dependencies in view of the cancellation of the intervening claims.

In view of the above, Applicants submit that the Amendments to the claims add no new matter and respectfully request their entry.

Response to the Rejection of Claims 5 and 29 under 35 U.S.C. §112, first paragraph.

The Examiner essentially found the scope of the compound subject matter of base claims 5 and 29 to be primarily described in terms of function and not structure and thus too broad to be enabled. Without acquiescing to the position of the Examiner and in order to expedite prosecution of the present application, the base claims 5 and 29 have therefore been amended to recite the compound subject matter of their respective dependent claims.

Response to the Rejection of Claims 5, 7-13 and 29-40 as allegedly unpatentable under 35 U.S.C. §103(a) over Protiva et al. (U.S. Patent No. 4,243,805) in view of Merck Manual of Diagnosis and Therapy (17th Edition).

Applicants further request the Examiner reconsider the propriety of the above rejection on the grounds that the inherency argument was improper.

The Examiner alleged that it would be obvious to treat a CMV infection with a neuroleptic agent in so far as:

- 1) Protiva shows that compounds for use according to the invention encompass useful neuroleptic and psychotropic agents.
- 2) The Merck Manual indicates that CMV infection can cause CNS damage and injury, typically during neonatal exposure; and
- 3) Michealson discloses that CMV infection can cause mental retardation and that CMV can replicate in a variety of cell types.

The conclusion of the Examiner appears to require the following scenario:

- 1) A person is posited who has a type of CNS disorder or CNS damage that is suited, rather than unsuited, for therapy with a neuroleptic agent.
- 2) The CNS disorder or damage happened to be caused by a CMV infection; in this regard Applicants acknowledge that CMV infection can cause a large variety of

neurological diseases (see enclosed article by van dan Pol et al., J. of Neuroscience 19 (24):10948-10965 (1999)).

3) A clinician happened to select a neuroleptic as set forth in the claims rather than another neuroleptic agent or an agent of another class altogether to treat the subject condition; and

4) The CMV infection is still present and active so that viral dissemination is that viral dissemination can be inhibited and the method of the invention thereby unwittingly accomplished.

The above rejection is based upon a theory of inherency. However, Federal Circuit decisions have repeatedly held that an inherent feature or result must be consistent, necessary, and inevitable, and not the *mere possibility* as set forth above¹. As the rejection is improper, Applicants respectfully request that it be reconsidered and withdrawn.

Response to the Rejection of Claims 5, 7-13 and 29-40 as allegedly unpatentable under 35 U.S.C. §103(a) over Sindehar et al. in view of Merck Manual of Diagnosis and Therapy (17th Edition) and Michelson Eur. (Cytokine Netw 10(2):286-7 (1999). al.

With respect to the neuroleptic activity of octoclotheptin and methiothepin, the above discussion of the disclosures of the Merck Manual and Michelson reference and a proper theory of inherency apply with equal force. As noted above, an inherent feature or result must be consistent, necessary, and inevitable, and not a mere possibility.

¹ See, e.g., Mehl/Biophile International Corp. v. Milgraum, 192 F.3d 1362, 52 USPQ2d 1303 (Fed. Cir. 1999); Atlas Powder Co. v. Ireco Inc., 190 F.3d 1342, 1347, 51 USPQ2d 1943, 1946 (Fed. Cir. 1999) ("To invalidate a patent by anticipation, a prior art reference normally needs to disclose each and every limitation of the claim. ... However, a prior art reference may anticipate when the claim limitation or limitations not expressly found in that reference are nonetheless inherent in it. ... Under the principles of inherency, if the prior art necessarily functions in accordance with, or includes, the claimed limitations, it anticipates."); Abbott Laboratories v. Geneva Pharmaceuticals, Inc., 182 F.3d 1315, 51 USPQ2d 1307 (Fed. Cir. 1999), *cert. denied*, 528 U.S. 1078 (2000), In re Robertson, 169 F.3d 743, 745, 49 USPQ2d 1949, 1950-51 (Fed. Cir. 1999) ("If the prior art reference does not expressly set forth a particular element of the claim, that reference still may anticipate if that element is 'inherent' in its disclosure. To establish inherency, the extrinsic evidence 'must make clear that the missing descriptive matter is necessarily present in the thing described in the reference, and that it would be so recognized by persons of ordinary skill.' ... 'Inherency,

A Showing of Surprising or Unexpected Results Rebutts the *Prima Facie* Case

The Action rightly pointed out that a surprising result can negate a *prima facie* case of obviousness. The Applicants point out that the specification teaches that administration of the subject compounds can inhibit CMV dissemination and are useful in treating CMV infection. With respect to the instant nonobviousness determination, Applicants submit that one of ordinary skill in the art would simply not have expected neuroleptic agents to also have antiviral, anti-CMV activity.

It is not mere attorney argument to point out the importance of the amino acid primary sequence to protein binding², and that therefore it is entirely surprising to find an agent that binds to a *mammalian* protein neurotransmitter receptor also binds to a *wholly* different *viral* protein receptor. Neuroleptic agents typically bind receptors for neurotransmitters (e.g., the dopamine receptor for octoclotheptin, the 5-HT receptor for methiothepin; see enclosed Sigma Catalog and Merck edition summaries). The fact that such compounds as recited in the claims also bind to the CMV US 28 receptor is certainly surprising. No *a priori* rationale has been set forth upon which such a surprising result could be deemed expected for these compounds. And any generally applicable rationale would be inconsistent with the Action's stated grounds for rejecting the enablement of the base claims for lack of structural definition. Nor, is there any requirement that a specification set forth a side-by-side comparison of the inventive method with the prior art method to support a surprising result. As to the alleged absence of any evidence of the surprising result, Applicants point out that specification teaches and exemplifies in Examples 2 and 3 compounds with such US 28 receptor binding properties. Applicants point out that the

however, may not be established by probabilities or possibilities. The mere fact that a certain thing may result from a given set of circumstances is not sufficient.' ");

² While it is known that many amino acid substitutions are possible in any given protein, the position within the protein's sequence where such amino acid substitutions can be made with reasonable expectation of success are limited. Certain positions in the sequence are critical to the three-dimensional structure/function relationship, and these regions can tolerate only conservative substitutions or no substitutions. Residues that are directly involved in protein functions such as binding will certainly be among the most conserved (Bowie et al. Science, 247:1306-1310, 1990, p. 1306, col. 2 (enclosed)).

Appl. No. 09/944,163
Amdt. dated March 15, 2004
Amendment under 37 CFR 1.116 Expedited Procedure
Examining Group

PATENT

instant Action has implicitly acknowledged the methods claims reciting the compounds of Formula I are enabled.

In view of the above, Applicants also request that both the above grounds for rejection be reconsidered and withdrawn.

CONCLUSION

In view of the foregoing, Applicants believe all claims now pending in this Application are in condition for allowance and an action to that end is respectfully requested.

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 925-472-5000.

Respectfully submitted,



Frank J. Mycroft
Reg. No. 46,946

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 415-576-0300
Attachments
FJM:fjm
60165328 v1

Cytomegalovirus Cell Tropism, Replication, and Gene Transfer in Brain

Anthony N. van den Pol,¹ Edward Mocarski,³ Noah Saederup,³ Jeffrey Vieira,⁴ and Timothy J. Meier²

¹Department of Neurosurgery, Yale University Medical School, New Haven, Connecticut 06520, Departments of

²Biological Science and ³Microbiology and Immunology, Stanford University, Stanford, California 94305, and

⁴Department of Laboratory Medicine, University of Washington, Seattle, Washington 98109

Cytomegalovirus (CMV) infects a majority of adult humans. During early development and in the immunocompromised adult, CMV causes neurological deficits. We used recombinant murine cytomegalovirus (mCMV) expressing either green fluorescent protein (GFP) or β -galactosidase under control of human elongation factor 1 promoter or CMV immediate early-1 promoter as reporter genes for infected brain cells. *In vivo* and *in vitro* studies revealed that neurons and glial cells supported strong reporter gene expression after CMV exposure. Brain cultures selectively enriched in either glia or neurons supported viral replication, leading to process degeneration and cell death within 2 d of viral exposure. In addition, endothelial cells, tanycytes, radial glia, ependymal cells, microglia, and cells from the meninges and choroid were infected. Although mCMV showed no absolute brain cell preference, relative cell prefer-

ences were detected. Radial glia cells play an important role in guiding migrating neurons; these were viral targets in the developing brain, suggesting that cortical problems including microgyria that are a consequence of CMV may be caused by compromised radial glia. Although CMV is a species-specific virus, recombinant mCMV entered and expressed reporter genes in both rat and human brain cells, suggesting that mCMV might serve as a vector for gene transfer into brain cells of non-murine species. GFP expression was sufficiently strong that long axons, dendrites, and their associated spines were readily detected in both living and fixed tissue, indicating that mCMV reporter gene constructs may be useful for labeling neurons and their pathways.

Key words: virus; neuron; GFP; development; mouse CMV; gene therapy; neuropathology

Cytomegaloviruses (CMVs) are a widespread group of double-stranded DNA viruses that infect many different mammals in a species-specific manner. Human cytomegalovirus (hCMV) is commonly found in humans where virus distribution among adults ranges from 50 to 90% of the population (Mocarski, 1996; Johnson, 1998). Similarly, murine CMV (mCMV) is ubiquitous in wild mice. Both CMVs have large genomes consisting of ~230 kilobase pairs (kbp) exhibiting low level nucleotide sequence homology outside the *ie1* region transcriptional enhancer and genome packaging signals but retaining colinear genome organization. Although similar in virion morphology, effect on cells, pathogenesis, and biology, all CMVs exhibit striking species specificity (Osborn, 1982; Ho, 1991; Mocarski, 1996).

CMV is the leading viral cause of congenital birth defects (White and Fenner, 1994; Alford and Britt, 1996). CMV can cause substantial brain damage when infection occurs during early human development, resulting in epilepsy, microencephaly, microgyria, hydrocephalus, deafness, and decreased IQ (Bray et al., 1981; Bale et al., 1985; Hicks et al., 1993; Perez-Jimenez et al., 1998). CMV infections are found in ~1% of human births, and clear neurological damage is found in 10% of those infected

(Hicks et al., 1993) with a higher percentage of more subtle neurological damage probable (Johnson, 1998). The range of cell types that are involved remains poorly defined (Ho, 1991).

In contrast to early development, children and adults control infection with little apparent effect on the nervous system, in part because of an effective immune response that maintains the virus in a lifelong latency. In immunocompromised individuals, CMV can contribute to neurological deficits and mental disorders (Navia et al., 1986; Chimelli et al., 1992; d'Arminio Monforte et al., 1992; Fiala et al., 1993; Arribas et al., 1995). Increased levels of virus in the brain are often associated with later stages of HIV infection (Kalayjian et al., 1993), sometimes with cellular colocalization of CMV and HIV (Nelson et al., 1988).

Microgyri found in cases of congenital disease (Diezel, 1954) have been suggested to be caused by CMV-mediated deficits in blood supply possibly related to endothelial cell infection (Tsutsui, 1995) rather than a direct damage to neurons (Marques-Dias et al., 1984). Others have suggested that the primary cell involved is a glial cell, either microglia as studied in guinea pig (Booss et al., 1988) or possibly a monocyte-derived macrophage/microglia as described in humans (Pulliam, 1991). Neuron and astrocyte involvement has also been suggested in developing rodents (Tsutsui, 1995) and HIV-infected humans (Wiley et al., 1986; Wiley and Nelson, 1988). In many cases, a single cell type has been suggested as the primary substrate for infection, with little detectable involvement of other cell types.

The species specificity of this group of viruses (Mocarski, 1996) suggests that rodent CMVs, replication incompetent in human cells (Ho, 1991), might serve as vectors to introduce foreign genes into brain or brain cells. To this end we tested the hypothesis that

Received July 7, 1999; revised Sept. 7, 1999; accepted Sept. 24, 1999.

This work was supported by National Institutes of Health Grants NS10174, NS31573, AI30363, NS37788, and NS34887, and the National Science Foundation. We thank Y. Yang, and P. Gip for excellent technical assistance, and Drs. H. C. Heller, R. G. Phillips, J. Peipmeier, C. Duncan, and Ken Vives for suggestions, help, or cells used in these experiments.

Correspondence should be addressed to Anthony N. van den Pol, Department of Neurosurgery, 333 Cedar Street, Yale University Medical School, New Haven, CT 06520. E-mail: anthony.vandenpol@yale.edu.

Copyright © 1999 Society for Neuroscience 0270-6474/99/1910948-18\$05.00/0

Recombinant Murine CMV




Figure 1. Map of the *HindIII* K, L, and J fragments of murine CMV (K181+ strain). The murine CMV *ie1/ie2/ie3* transcriptional enhancer and the arrangement of *ie1*, *ie2*, *ie3*, *sgg1*, and *MCK* transcripts are also shown, with splicing patterns indicated on the arrows depicting individual transcripts as they appear in wild-type murine CMV. The *lacZ* insertion mutation in RM427+, the *EGFP-puro* insertion in RM4503–1, and the GFP–GPT insertion in MC.55 are depicted below the map. Expression of the *lacZ* gene in RM427+ was regulated by a 199 bp human CMV *ie1/ie2* promoter (α HCMV) fragment (–219 to +19 relative to the transcription start site) (Manning et al., 1992). Expression of the *EGFP-puro* gene in RM4503 was regulated by a 249 bp human CMV *ie1/ie2* promoter (–242 to +7 relative to the transcription start site). These promoters display immediate early expression kinetics when placed adjacent to the murine CMV enhancer (*Enh*) in the *HpaI* sites of the *ie2* gene (Manning et al., 1992; our unpublished observations). Expression of *EGFP* in MC.55 was regulated by the human elongation factor 1a promoter (*EF-1 α*) (Uetsuki et al., 1989), whereas the *E. coli* GPT was under the control of the mouse phosphoglycerate kinase (*PGK*) promoter.

mCMV would serve to introduce foreign genes into mouse, rat, and human brain cells. Although a previous analysis had suggested that neither human embryonic brain cells nor human cell lines were susceptible to mCMV entry or infection (Kim and Carp, 1971), more recent advances in molecular biology of recombinant viruses and reporter gene induction provide a more sensitive assay, as described here. We generated mCMVs expressing an enhanced green fluorescent protein (GFP) or β -galactosidase (β -gal) to study CMV infection and reporter gene expression *in vitro* and *in vivo* in live and fixed brain cells.

MATERIALS AND METHODS

Recombinant CMV. Recombinant viruses derived from the K181 strain of mCMV capable of expressing β -gal (RM427+) or enhanced GFP (EGFP) (MC.55 and RM4503) were used in these studies (Fig. 1). RM4503, like RM427 (Manning et al., 1992), was constructed to express a marker gene insert under control of a chimeric promoter-enhancer composed of an hCMV promoter-enhancer fragment (–242 to +7 relative to the transcription start site) inserted adjacent to the mCMV enhancer in the mCMV genome. This construct included an SV40-derived polyadenylation signal downstream of the marker gene and directed constitutive high-level expression of the marker throughout infection (Manning et al., 1992; Saederup et al., 2000). The EGFP-puro construct, a gift of Mark Prichard and Greg Pari (Hybridon Corporation, Cambridge, MA), fuses the entire EGFP protein coding sequence to the puromycin resistance protein coding sequence with an intervening five amino acid spacer. The expression cassette was inserted into the mCMV *ie2* gene, which has been shown to be completely dispensable for viral growth in cell culture as well as for growth, latency, and pathogenesis in BALB/c mice (Cardin et al., 1995). pON4503 was constructed by digesting pON4457, which carries a 6.6 kbp *DraI/EcoRI* fragment of mCMV DNA (nucleotide 183086–189674), with *HpaI*, cleaving at two closely spaced sites in the *ie2* promoter and cloning a 1.7 kbp *SnaBI/HpaI* fragment from EGFP-puro in the same transcriptional orientation as *ie2* (Fig. 1). Recombinant virus was created by co-transfection of NIH 3T3 cells with RM427+ DNA and *PacI/AflIII* digested pON4503 with Superfect (Life Technologies, Gaithersburg, MD) in OptiMEM (Life Tech-

nologies) followed by addition of standard DMEM (Life Technologies) supplemented with 10% NuSerum (Fisher Scientific, Pittsburgh, PA) and antibiotics as described (Vieira et al., 1994). Recombinant viruses were isolated by plaque assay from supernatants collected at 7 d after transfection. Recombinant virus was enriched by replacing standard medium with medium containing puromycin (5 μ g/ml) (Sigma, St. Louis, MO) for the final 2 d and during one additional round of growth after which ~80% of plaques exhibited green fluorescence. Enriched pools were used to inoculate BALB/c mice by the intraperitoneal route; progeny virus was recovered from salivary glands 14 d after inoculation and was followed by two rounds of limiting dilution purification at which time RM4503 was judged pure and authentic by the absence of any β -gal-positive virus and by DNA blot hybridization of viral DNA restriction fragments. Green fluorescence was detectable as early as 6 hr after infection with plaque-pure RM4503 in NIH 3T3 cells. RM4503 grew as well as wild type in cell culture and, after intraperitoneal inoculation, reached titers similar to wild type in salivary glands.

A second recombinant mCMV (Fig. 1, MC.55) containing the GFP gene was constructed using pON488, which is composed of the *DraI* (position 183086) to *Clal* (position 188569) fragment of mouse CMV (Rawlinson et al., 1996) containing the immediate early-2 gene cloned into pUC21, which had been cut with *PstI* (made blunt with Klenow fragment and all four deoxynucleotides) and *Clal*. A cassette consisting of the EGFP gene (Clontech, Palo Alto CA) under the control of human elongation factor 1a promoter (Uetsuki et al., 1989), and the *Escherichia coli* guanosine-hypoxanthine phosphoribosyltransferase gene (GPT) under the control of the mouse phosphoglycerate kinase (PGK) promoter, was inserted between the *HpaI* (position 184236) and *NheI* (position 187119) sites of pON488 to create pQ55. For the transfection of NIH 3T3 cells, pQ55 was digested with *SalI*, extracted with phenol/chloroform (24:1) and chloroform, ethanol-precipitated, dried, and suspended in STE (5 mM NaCl, 5 mM Tris-HCl, pH 7.5, 1 mM EDTA) at a concentration of 1–2 mg/ml. For electroporation, 2×10^6 to 5×10^6 NIH 3T3 cells plus 20 mg DNA in 0.4 ml of electroporation buffer [a 1:3 mixture of OptiMEM I (Life Technologies) and cytomix (van der Hoff et al., 1992) (120 mM KCl, 0.15 mM CaCl₂, 10 mM K₂HPO₄/KH₂PO₄, pH 7.6, 5 mM MgCl₂)] were electroporated with a BTX ECM 600 instrument set at 275 V and 1075 mF in a 4 mm cuvette at room temperature. Cells were plated after electroporation and infected with mCMV at a multiplicity




Figure 2. Glia infection *in vitro*. *A*, After 30 hr, most astrocytes *in vitro* were green, indicating infection with mCMV. Scale bar, 8 μ m. *B*, By 54 hr, most glia were dead or dying and had a round featureless shape. Scale bar, 25 μ m. *C–E*, Olfactory ensheathing cells (*olf.e.c.*) became green 30 hr after infection with CMV. Scale bar, 12 μ m.

of infection (MOI) of 2–5 at 18 hr after electroporation. Progeny virus from the transfection/infection cultures were grown for two rounds under selection for the GPT gene as described (Vieira et al., 1994) to enrich for recombinant virus. Recombinant virus, identified by green fluorescent plaques under 488 nm illumination, were ultimately purified by twofold limiting dilution. In this MC.55 recombinant virus the *ie2* gene, which is dispensable for growth (Cardin et al., 1995), is disrupted. Viability of mCMV was expressed as plaque-forming units (pfu) determined before the virus was frozen in stock solutions at -80° for future use.

Viral replication. If virus replicates in the brain cultures, then as time progresses, the culture supernatant should show an increased concentration of infectious virus. To test this, rat (Sprague Dawley) neurons from hippocampus, hypothalamus, and cortex were mixed and plated in 35-mm-diameter wells at a density of 10^6 cells/well. Parallel experiments were performed with mouse (BALB/c) neurons. Each condition was performed in triplicate. Brain cultures were infected with either of two different GFP-expressing viruses. The MC.55 virus was used at 10^6 pfu, and RM4503 was used at 5×10^5 pfu. At 6 hr after inoculation, brain cultures were washed four times to remove the unadsorbed inoculum and placed in 2 ml growth medium. At 18 hr after the initial infection, all tissue culture medium supernatant (2 ml) was collected and replaced with 2 ml sterile culture medium. Culture medium contained DMEM supplemented with 10% fetal bovine serum (Hyclone, Logan, UT). Additional collections were made at successive 12 hr intervals. Tissue culture supernatant containing CMV was frozen within minutes after collection and kept at -80° C.

To determine relative viral concentration, NIH 3T3 cells were grown on 12-mm-round coverslips until the cells were 60% confluent. Then a 500 μ l aliquot from each of the test conditions was added to the 3T3 cells. After 18 hr, all 3T3 cells were killed with 3% paraformaldehyde overnight. After washing in phosphate buffer, 3T3 cells were examined in an inverted Nikon epifluorescent microscope using a 20 \times Olympus objective. Green fluorescent 3T3 cells were counted in eight visual fields on each 3T3-containing coverslip.

Because CNS cultures contain a mixture of glia and neurons, in a second set of experiments we used more selective cultures enriched in glia or neurons to infect with MC.55, as described above. Glia were obtained from postnatal day (P) 5 mouse cortex. Glia were plated at low density and then allowed to replicate until they were 75% confluent in a 35 mm culture dish. Neurons were obtained from a P6 cerebellum. These cultures consist primarily of cerebellar granule cells, neurons that undergo their final mitosis at approximately this stage of development, substantially later than most neurons. A more detailed description of granule cell (Liljelund et al., 1994) and astrocyte (van den Pol et al., 1992) enriched cultures is found elsewhere. Granule cells were also plated at 75% confluency. Both cell types in these experiments were maintained with Neurobasal media (Life Technologies) for 4 d before viral contact. To avoid glial proliferation after viral infection, fetal bovine serum was not used during those 4 d or thereafter. Medium was harvested and replenished every 12 hr, as described above, and experiments were performed in duplicate.

Virus in CNS. To determine whether mCMV would infect brain cells *in vivo*, 500 nl–1.5 μ l (10^3 pfu/nl) of virus was injected with a Hamilton microsyringe directly into the brain. Mice from P1 to adults were used. Adult rats also received intracerebral injections at the same virus concentration. Injections were aimed so that the tip of the syringe needle would pass through the cerebral cortex and end in the striatum, hippocampus, or hypothalamus. To reduce a sudden increase in local pressure, the virus was injected slowly over 2–3 min.

Microscopy. Photomicrographs were taken on an Olympus IX70 inverted fluorescent microscope with a Spot 2 digital camera (Diagnostic Instruments) interfaced with a Macintosh computer. Contrast was adjusted with Adobe Photoshop, and images were printed on a Kodak 8650 dye sublimation digital printer.

RESULTS

Viral infection of neurons and glia *in vitro*

To examine the course of CMV infection of brain cells, developing brains were cultured on glass coverslips and studied after incubation with GFP-expressing mCMV (either RM4503 or MC.55) or β -gal expressing mCMV. Within 6 hr of viral addition to the culture (MOI = 15), some neurons and glia began to show GFP-mediated green fluorescence or β -gal staining with each of




Figure 3. Mouse neurons *in vitro*: brief infection. *A*, A montage of a neuron *in vitro* for 5 d, 2 d after mCMV infection. Processes are labeled. Scale bar, 22 μ m. *B*, A neuron with wide dendrites and a thin axon-like process in box. *C*, Higher magnification of box in *B*, showing a bright GFP-expressing axonal process growing on top of the dendrite. *D*, Axonal arbor 2 d after mCMV introduction.

the three viruses used. In cultures containing both glial cells and neurons, a greater number of astrocytes showed GFP labeling than did neurons at earlier time points. Within the next 24 hr, a greater number of cells showed expression of the reporter genes. In parallel, the expression of both GFP and β -gal became much stronger. In cultures containing roughly equal numbers of astrocytes and neurons, 96 astrocytes were labeled and only four neurons were found after 18 hr. The ratio changed over time, with greater numbers of neurons showing evidence of infection. Mouse brain cultures contained a mixture of neurons, astrocytes,

and oligodendrocytes, as identified with immunolabeling for L1 (neurons), glial fibrillary acidic protein (astrocytes), and myelin basic protein (oligodendrocytes) antisera, as described previously (van den Pol et al., 1992; van den Pol and Kim, 1993; Liljelund et al., 1994).

Some cultures of hypothalamus, cortex, and hippocampus ($n = 6$ each) were infected with mCMV at an MOI of 15. Interestingly, all cells, including neurons, astrocytes, and oligodendrocytes, died within 48 hr. This finding was based both on fluorescent microscopy and the use of video-enhanced differential interfer-




Figure 4. Mouse neurons *in vitro*: extended infection. *A*, Four days after infection axons show a greater degree of beading than seen in control cultures. *B*, *C*, Some axons in late stages of degeneration show only a few poorly connected swellings that are fluorescent. Scale bar, 10 μ m. *D*, Two somata are seen with unusual round shapes and are devoid of processes 5 d after infection. Scale bar, 12 μ m.

ence contrast (DIC) microscopy used to detect nonfluorescent cells. Ethidium homodimer (Molecular Probes, Eugene, OR), which labels the nuclei of dead cells, was also used to assess cell viability. In cultures made from postnatal day 2 glial cells from hippocampus, by 30 hr after infection, most astrocytes that had a typical sheet-like flat appearance were green, indicating infection with mCMV (Fig. 2*A*). After 48 hr, cells either were detached and floating or broken down with no cellular continuity; the cells still attached to the substrate were bright green and round, exhibiting viral cytopathic effects (Fig. 2*B*). In contrast, noninfected control cultures generated at the same time showed little evidence of cell death, suggesting that all types of brain cells can be killed by a high concentration of virus. When a lower dose of virus (MOI = 1) was used, cells survived much longer, with some neurons and glia still viable after 7 d. With time, however, all mouse brain cells died, whereas same-age noninfected controls

remained viable. Although all infected cells expressed the reporter genes, consistent with infection, the level of expression varied with time and dose of virus. The highest level of reporter gene expression came with longer survival times achieved with lower MOIs. This may have been because cells infected with high MOIs (>14) died before the higher levels of gene expression could be achieved.

Earlier work on virus penetration into the brain suggested that the olfactory mucosa might be a potential portal of entry for virus into the brain by spread along the olfactory nerve as it entered the olfactory bulb. A primary cell type that encircles the olfactory axons is the olfactory ensheathing cell, a type of glial cell. Cultures of mouse olfactory ensheathing cells showed strong GFP expression after infection with mCMV (Fig. 2*C–E*). That the cultured cells were primarily ensheathing cells was confirmed with immunostaining for P75, the low-affinity NGF receptor that these cells selectively express (Vickland et al., 1991; Ramon-Cueto and Valverde, 1995).

In control cultures, and in early stages of viral infection, neurons showed long processes that included both dendrites several hundred micrometers in length and axons exceeding 1000 μ m in length. After mCMV infection, neurons initially began to turn green with no obvious sign of pathology (Fig. 3). However, soon after the neurites showed a green coloration, they began showing unusual dilations and constrictions in processes, some reaching several micrometers in diameter. Green processes were only found after the parent cell body showed reporter gene expression indicative of viral infection and gene expression. At a later stage of infection, processes began to break down and become strongly segmented (Fig. 4). At late stages of infection, parts of green processes could be found without connection to the cell body of origin (Fig. 4), and round cells devoid of processes were common (Fig. 4). These process dilations were not found in noninfected control cultures. With mCMV MOI of 15, the time course for neuronal degeneration was complete within 2 d, as determined in >20 cultures; with lower MOI (= 1), the time course could be extended.

During later stages of infection, some groups of cells appeared to fuse together and had the appearance of giant multinucleated cells. These giant "cells" had diameters from 40 to 60 μ m, with large ones approaching 200 μ m. The largest of these appeared to be composed of >30 cells or nuclei (Fig. 5*C, D*). These cells showed continuous strong green fluorescence, suggesting that the outer membrane was intact. No giant cells were found that were not green, underlining the importance of viral infection and subsequent GFP expression. At later stages of infection, and after cell lysis, GFP was liberated into the culture medium, and the remaining cellular debris showed only faint green fluorescence. Giant multinucleated cells were not found in any control cultures. In culture dishes that contained giant cells, other groups of cells were found where the individual cells were not contained with a single membrane and therefore were not considered giant cells (Fig. 5*A, B*). Parallel detection of giant cells after CMV infection in humans has been reported (Belec et al., 1990; Horn et al., 1992). The presence of giant cells suggests that CMV mediated fusion of the outer plasma membranes of different cells.

Viral replication

To assess viral replication in neurons and glia, tissue culture supernatant was taken at intervals after initial infection of brain cell cultures and complete washout of mCMV. The relative density of viral production was assessed by incubation of the




Figure 5. Giant cells after mCMV infection. DIC images are shown on the *left*, and on the *right* are shown the same field with fluorescent microscopy for detecting GFP. *A, B*, Three days after infection of a mixed neuronal–glial culture, a small group of cells are tightly packed together but do not show characteristics of a giant cell. *C, D*, A giant cell appears to be composed of many other cells fused together and is seen with a few cells attached on the *outside* to the *left*. In *C*, the DIC image shows a relatively smooth outer membrane (*arrows*). Within the giant cell, a heterogeneous GFP-mediated fluorescence is seen, suggesting that there is not total cytoplasmic continuity at this point. Scale bar, 16 μm .

extracted media with a second set of cultures containing NIH 3T3 fibroblasts, which are a fully permissive cell line for plaque assay and virus propagation. GFP-labeled 3T3 cells were then counted after 18 hr. 3T3 cells were used here because they are a common permissive host cell for raising CMV. The number of green 3T3 cells incubated with virus for a fixed period (18 hr) increased with time (Fig. 6). In the initial test 18 hr after virus introduction into brain cell cultures, little evidence of virus was found in the brain culture supernatant. As the infection proceeded, the relative number of viral progeny that were produced increased dramatically, as deduced from the proportion of 3T3 cells that became green. Eight circular fields of 500 μm diameter were counted per 3T3-containing coverslips, which had a total area of $113 \times 10^6 \mu\text{m}^2$.

Viral replication of two GFP-expressing mCMVs (RM4503 and MC.55) was compared in rat and mouse brain cultures (Fig. 7). When a three-way ANOVA was used to test for statistical differences between conditions (virus \times brain species \times survival after virus infection), a significant difference was found ($p < 0.001$). To make more discrete comparisons, a Tukey test was

used. This revealed that each of the viruses used (RM4503 and MC.55) showed an increase in number over time ($p < 0.05$), with a slow initial rise time, followed by substantial increases in virus. Although the rate of replication was substantially lower in rat cells than in mouse cells ($p < 0.05$), viral replication was observed in rat brain cultures infected with the MC.55. However, little GFP was expressed in 3T3 cells incubated with tissue culture supernatant from rat cultures infected with a second virus, RM4503. This may be attributable to strain differences between RM4503 and MC.55. It could also be attributable in part to a lower general level of fluorescence found with RM4503, reducing detection in infected cells, or to a lower initial concentration of virus.

The cultures described above contained a mixture of glia and neurons. To examine viral proliferation in more selective cultures, glial-enriched cultures were compared with cultures enriched in cerebellar granule cell neurons (Fig. 8), each growing at roughly 75% confluency, and tested with neuron- and astrocyte-specific antisera, L1 and GFAP, respectively. After inoculation with MC.55 (10^6 pfu per dish), the glia cultures showed a more




Figure 6. 3T3 test cultures used for viral replication test. *A*, DIC image of NIH 3T3 culture incubated with tissue culture supernatant from brain cultures that had been infected for 18 hr. *Arrow* identifies a single cell. *B*, Same field as in *A*, showing a single fluorescent 3T3 cell (*arrow*). *C*, In parallel cultures, DIC imaging shows a group of 3T3 cells, one identified with an *arrow* to facilitate recognition in DIC and fluorescence. *D*, With fluorescent microscopy of the same field, most of the cells express GFP-mediated fluorescence. Tissue culture supernatant was taken from brain cultures 42 hr after mCMV infection. In both sets of experiments, 3T3 cells were examined 18 hr after their initial incubation with brain culture supernatant. Scale bar, 25 μ m.

rapid cell death than occurred in the neuronal cultures (Fig. 9). Analysis of virus replication showed that culture supernatant had low levels of virus during the first 18 hr, but then began to rapidly increase. By 42 hr, sufficient virus was produced to infect almost all of the 3T3 test cells. By 54 hr, approximately half of the glial cells showed signs of lethal infection, determined by cell swelling, detachment, and loss of cell number. At that time, most of the cells began to detach from the substrate, some even retaining high levels of GFP expression, suggesting that the plasma membrane was still intact. Because less than half of the astrocytes remained after 54 hr, samples were not tested further for release of virus progeny.

In contrast, the neuronal-enriched cultures showed a substantial delay of reporter gene expression with ~25% of the neurons showing detectable GFP after 54 hr, a time when all glial cells were infected and more than half the glia were dead. However, with time the number of neurons showing GFP expression increased. After 3 d of CMV infection, both infected and noninfected control cultures of granule cells showed strong neuritic extension. These were primarily composed of long bundles of

granule cell axons and characteristically short granule cell dendrites. Interestingly, 5 d after mCMV infection, little evidence of neurites was found in the infected culture, whereas control cultures showed vigorous neuritic outgrowth, suggesting that mCMV caused a profound reduction in neurites (Fig. 8). Cells in the neuronal enriched cultures survived for a longer time than cells in the glial enriched cultures. Analysis of viral replication in 3T3 cells showed that 102 hr (4 d) after initial infection, sufficient virus was produced to turn all 3T3 test cells green. The rate of viral replication was significantly slower in neuronal cultures than found in glial cultures prepared at the same time (ANOVA, $p < 0.01$).

Viral infection of mouse brain *in vivo*

mCMV was microinjected at a single site in neonatal or adult mouse brains. After fixation and sectioning, the presence of mCMV was detected by the presence of either fluorescent GFP or x-gal staining in the presence of β -galactosidase. Peroxidase immunostaining with antisera against GFP was also used as a sensitive means of detection. Of nine adult mice injected (5×10^5




Figure 7. mCMV replication enhanced in mouse brain cultures. *A*, Using MC.55 that was engineered to express GFP under control of elongation factor 1 promoter, viral replication in brain cell cultures was studied by harvesting culture supernatant and determining the number of 3T3 cells that showed GFP expression. Mouse brain culture supernatant generated strong GFP label in an increasing number of 3T3 cells, to the point that all 3T3 cells in culture were labeled with medium from cultures 3 d after mCMV infection. Rat cultures showed a low level of viral replication. Forty-eight thousand 3T3 cells were plated per coverslip; the plateau between the last two mouse points was not attributable to a decrease in viral replication but rather to the fact that the maximum number of test 3T3 cells (48,000) had turned green. *B*, Parallel experiments were performed with the mCMV under control of the human CMV promoter (RM4503). Replication was found in mouse brain cultures but at a lower rate than found with MC.55. With this viral strain, replication in rat brain cultures as deduced by GFP expression in 3T3 cells was minimal.

pfu, 500 nl), none died in the 1–6 d after the injection. In contrast, of 17 mice injected at P1 or P2, nine (53%) died in the following 4 d. mCMV injections into P3 mice were lethal to 4 (40%) of 10 mice by 6 d after infection.

Many different cell types in the brain showed evidence of viral infection. Robust expression of β -gal and GFP was seen in the meninges (Fig. 10*A,B*) and choroid plexus (Fig. 10*F*). Some of the ependymal cells lining the third and lateral ventricles also were β -gal or GFP positive (Fig. 10*D,E*). A recent report has suggested that ventricular ependymal cells may serve a role as neuronal stem cells (Johansson et al., 1999). If CMV causes loss of these cells, this may reduce potential neurogenesis, exacerbating problems in the developing brain. Endothelial cells lining the blood vessels showed indication of viral presence, particularly in the region of the injection (Fig. 10*C*). In addition, virus-infected

endothelial cells were found at a considerable distance from the injection site, suggesting spread of the virus through the vasculature.

In older mice, in the third ventricle, infected cells included tanycytes, long radial glia that are present in both developing and mature brain with the cell body in the wall of the ventricle. In developing mice, dramatic expression of GFP was found in radial glia in many brain areas, particularly near a site of injection. Radial glia serve as important cellular guides for neuronal migration during early development (Rakic, 1978). In the cerebral cortex, label was found in cell bodies of the radial glia in the deeper regions of the cortex and in the long processes that stretched outward, dividing into small endfeet at the pial surface of the cortex surface (Fig. 11*A,B*). Some infected radial glia showed signs of degeneration, characterized by abnormal swelling along the long glial process in both the inner (Fig. 11*C*) and outer (Fig. 11*D*) cortex. These process dilations appear similar to process degeneration found in infected cultures. Although neurons and astrocytes greatly outnumber radial glial in general numbers in normal mice, in some developing mice (<5 d old) these radial glia accounted for most of the cells infected by mCMV in affected areas of the cortex.

Some intracerebral injections of virus were made into different brain regions, including cortex, hippocampus, striatum, and hypothalamus. Particularly striking was the strong presence of virus in glial cells with the appearance of astroglia around the injection site. In addition, neurons were infected with virus; these cells had dendritic and axonal processes typical of neurons (Fig. 12). A large number of cases were found in many parts of the brain where neurons appeared to be the primary cell infected. Isolated neurons were found in the cortex (Fig. 12*A*), hypothalamus (Fig. 12*B*), and hippocampus (Fig. 12*C*). Of potential importance, some GFP-expressing neurons were found at considerable distances from the injection site. This could have been caused in part by diffusion of the virus at the time of injection. However, in a number of cases, a random distribution pattern of the virus in distal regions of the brain was not found. Instead, a GFP-filled process could be followed from the labeled cell into the zone of brain damage elicited by penetration of the injecting microsyringe needle. This suggests that the virus may be transported within the neuron process back to the cell body where the virus entered the nucleus to express GFP. Many labeled axons were found far from the injection site (Fig. 12*D–F*), including in the white matter of the corpus callosum (Fig. 12*E*).

Similar to neurons in culture, neurons *in vivo* that showed GFP expression several days after viral infection showed severe symmetrical dilations and constrictions along long axons. Some of the dilations reached 5 or 6 μ m in diameter; such large dilations were not seen in noninfected control axons. This type of dilation was also not found in control brain tissue labeled with DiI or horseradish peroxidase injections, suggesting that it was not an artifact of fixation or histological processing.

In developing mouse brains, intracerebral injections of mCMV can cause strong labeling of hippocampus. As shown in Figure 13*A*, cells surrounding the neonatal hippocampus show strong viral infection. Within the hippocampus, neurons and their processes are infected with the virus (Fig. 13*B*).

We found a number of cells that were clearly infected with mCMV, detected with expression of the viral GFP, but the infected cell showed little evidence of cytomegaly, the characteristic pathological determinant of CMV infection. This was true both in cultured cells and in histological sections from the brain.




Figure 8. Cerebellar granule neurons. *A*, Four days after mCMV (MC55) infection of a culture enriched with granule cells, many of the cells show bright GFP fluorescence. The same cell is indicated by an arrow in *A–c'* to facilitate recognition. *B*, Same field as in *A* but with partial fluorescence, partial phase contrast. Some cells seen in phase contrast are not fluorescent. *C*, Same field as in *A* but only with phase contrast. Scale bar, 100 μ m. A higher magnification of *C* is shown in *c'* (arrow). Neurites are not found in these infected neurons. *D*, Control granule cell culture not infected with mCMV shows no fluorescence. *E*, Phase-contrast photomicrograph of culture 2 d after infection. Neurites are commonly found spreading out from groups of neurons, shown in higher magnification in *e'*.




Figure 9. mCMV replication in cultures enriched in astrocytes or neurons. Cultures enriched in cerebellar granule cells (neurons, ●) or astrocytes (○) were infected with MC55. Viral replication was more rapid in the cultures enriched in astrocytes. Neuronal cultures also showed viral replication, but at a slower rate. Forty-eight thousand 3T3 cells were plated per coverslip.

Thus some of the earlier reports suggesting a selective lack of infection of one type or another in the brain may simply be due to the absence of cytomegaly and the subsequent inability to detect infected cells. Histopathological detection of cytomegaly in tissues is insensitive but in the past has been used widely to search for evidence of CMV infection. The use of cytopathology as a marker for CMV infection at the cellular level is further complicated by the finding that induction of apoptosis in noninfected neurons can be generated by a secondary signal from CMV-infected cells in mice (Kosugi et al., 1998). The use of reporter genes as described here appears to be a more sensitive mode of assessment of mCMV presence than the cytomegaly commonly associated with CMV. Unlike approaches based on histological processing that may also be sensitive, for instance *in situ* hybridization (Myerson et al., 1984; Slobedman and Mocarski, 1999), our approach, particularly with GFP, does not require fixation or histochemical treatment.

Gene transfer to rat and human

The experiments with mouse brain cells suggested that mCMV might be a potentially useful vector for gene transfer into mouse brain cells. Given the potential toxicity of the virus to mouse cells, the virus would probably not be ideal for any beneficial action. However, because replication of CMVs is to a large degree species specific, we sought to determine whether CMV could be used for gene transfer to other species. To this end, we used rat and human cells *in vitro* and rat brain *in vivo*.

Rat brain

After mCMV infection, cultures of rat brain showed GFP expression in both neurons and astrocytes. Microglia, identified by immunolabeling with an antibody against rat CD11b/c (Cedarlane Labs, Hornby, Ontario, Canada) that binds to brain microglia and macrophages (Robinson et al., 1986), also showed GFP expression. There was also a low level of viral replication in rat brain cultures, as described earlier.

In an *in vivo* set of experiments, mCMV was directly injected into rat brains ($n = 12$). After periods ranging from 1 to 7 d, animals (eight adult rats, four P5 rats) appeared healthy; no rat

death was attributed to the mouse CMV. At or near the site of mCMV injection, strongly labeled neurons were found in hypothalamus, hippocampus, striatum, and cerebral cortex (Fig. 14*A,B,D,E*). In the example in Figure 14*A,B,D*, adult striatal neurons showed very strong GFP labeling with little detectable GFP in the surrounding glial cells. Single axons and bundles of long axons could be followed from the striatal area several thousand micrometers toward the midbrain (Fig. 14*C*), and local axons were abundant around labeled cells. Spiny neurons in the striatum could be identified by the strong labeling in the dendritic spines (Fig. 14*B*). Despite the strong neuronal labeling in the striatum, relatively few cells with the morphology of glial cells could be found. Although the injection site included both cortex and striatum, the level of neuronal labeling in the striatum was dramatically stronger than in the cortex, suggesting some preferential infection of the virus.

In its role as a vehicle for gene transfer, recombinant mCMV that expresses GFP may prove useful for some aspects of exploring neuronal circuitry and cell structure. This would not be limited to mouse, because we found strong labeling in rat brain and cultured human brain cells, suggesting that mCMV might also work in other species. Previous work with pseudorabies virus (Card et al., 1990, 1991, 1999), herpes simplex virus (Ho et al., 1995; Meier et al., 1998), and lentiviruses based on HIV vectors with CMV promoters (Blomer et al., 1997; Miyoshi et al., 1997) has demonstrated the effectiveness of viral vectors in the brain.

Human brain

Although earlier studies suggested that mCMV did not infect human cells (Kim and Carp, 1971), in our hands human cells cultured from a brain astrocytoma showed intense green labeling after introduction of MC55 (MOI = 2), indicating robust expression of the transgene under control of the human elongation factor 1 α promoter (Fig. 15*A–C*). Most of the human cells that showed infection on the basis of GFP expression showed little evidence of cytomegaly. The longest experiments in this series lasted 1 week, but because human cells continued to show strong fluorescence at this time, it is likely that expression would have continued for a longer period. In contrast, the number of mouse brain cells expressing GFP increased over time, so that after 1 week all mouse cells were dead or green, suggesting viral replication and *de novo* infection of additional generations of brain cells. In contrast to mouse brain cell cultures, there was no striking increase over time in the number of human brain cells that showed GFP expression, consistent with a lack of replication of the mCMV. Previous work with human CMV has demonstrated its presence in human astrocytes and astrocyte-related tumors (Duclos et al., 1989; Ho et al., 1991; McCarthy et al., 1995). MC55 (MOI = 2) also infected cultures of a cell line of human neuroblastoma cells (gift of Dr. K. Vives, Yale University). These cells also showed strong levels of GFP expression (Fig. 15*D,E*).

Both of the experiments above were performed with human cells derived from a tumor and show abnormally high rates of cell division *in vitro*. Cells were also cultured from “normal” human cortex, removed surgically to provide access to a more ventral lesion. These cells replicated very slowly and appeared normal in culture. When these cultures were infected with mCMV (MOI = 2), cells with a flat sheet-like morphology typical of astrocytes showed GFP expression indicating viral infection and gene expression. In a typical culture well 2 weeks after low-density culturing of the human cells, and within 30 hr of CMV addition,




Figure 10. Intracerebral injections into mouse brain. mCMV injections were made into the lateral hypothalamus, with the syringe needle passing through and releasing virus into the ventricular system. *A*, The ventral region of the brain that includes the lateral hypothalamus (right of arrow). Scale bar, 65 μ m. *B*, Same field as in *A*; shows GFP labeling of the meninges (arrow). *C*, Cells surrounding the blood vessels (arrows, *bv*) of the mammillary bodies after nearby injection of mCMV; the GFP label was stained with immunoperoxidase. *D*, Ependymal cells (arrows) of the lateral ventricle (*lat V*) are labeled (arrow) after immunoperoxidase staining of GFP. *E*, Some of the ependymal cells of the third ventricle (*3rd V*) show viral infection after x-gal staining for β -gal. *F*, Many cells of the choroid plexus are labeled after injection of the β -gal expressing mCMV.

all 47 cells with the flat sheet-like morphology typical of astrocytes showed GFP expression, indicating viral gene expression (Fig. 15*F*). At 2 weeks after infection, the longest interval studied, green cells were still found in these cultures.

DISCUSSION

CMV cell preference is relative, not absolute

In the present study we found that all different types of cells in the brain can be infected with mCMV. This includes neurons, astro-

cytes, ependymal cells lining the ventricles, ventricular tanycytes, radial glia, endothelial cells of the capillaries, ensheathing cells of the olfactory bulb, meninges, microglia, and cells of the choroid plexus. These data support the view that mCMV in the brain is an opportunistic virus, with no single cellular target. However, there was strong evidence that related subsets of cells showed a higher incidence of GFP expression, suggesting some viral preference. An example of this was the high probability of striatal neuron infection coupled with the low incidence of infection in




Figure 11. Preferential infection of radial glia in developing mouse cortex. *A*, In mouse cortex, radial glia appear to be the primary cells infected after mCMV injections into the P2 mouse. Long processes travel from the cell body layer (arrow) and ascend to the outer cortical surface. The syringe needle passed through the cortex and into the hippocampus, and cells were labeled in both places. Scale bar, 50 μ m. *B*, In the same brain, near the midline, a number of processes cross the corpus callosum and continue through the developing gray matter. Scale bar, 15 μ m. *C*, *D*, Processes of mCMV-infected radial glia in the deep cortex (*C*) and outer cortex (*D*) show dilations (small arrows) suggestive of pathology. Some dilations reach almost 10 μ m in diameter. Other processes (long arrow) show no dilations. Scale bars: 20 μ m. All micrographs here are after peroxidase immunostaining of GFP.

glial cells in the same brain region, and the strong infection of cortical radial glia, discussed below. This could be attributable to differential cell-virus adhesion and cellular uptake, viral replication, or differences in cellular activators of the promoters for the gene reporters used. Some neurotrophic viruses, for instance pseudorabies virus (Card et al., 1990, 1991, 1999) or herpes simplex-1 (Dash et al., 1996), may be selective for subsets of neurons. In the present study we found evidence for infection of various neuronal types from cortex, hippocampus, striatum, and hypothalamus.

In our studies examining viral replication, mouse cultures enriched in either astrocytes or neurons showed evidence of strong mCMV replication. Virus number peaked more rapidly in astrocyte cultures than in neuronal cultures. This could be attributable in part to a greater level of replication in glial cells, although this was minimized by the use of defined medium not including serum and not favorable for astrocyte mitosis. Alternatively, although the cultures showed similar levels of confluency at the time of infection and were infected with equal amounts of virus, the glial cultures received a higher MOI, given the larger size of astrocytes




Figure 12. Mouse neuronal infection by mCMV. Neurons in the mouse brain were infected with mCMV as shown after immunoperoxidase staining of GFP in the cerebral cortex (*A*, scale bar, 12 μ m), hypothalamus (*B*, scale bar, 20 μ m), and hippocampus (*C*, scale bar, 25 μ m). Axons show GFP label with no nearby neuronal cell body labeling, as shown in *D* (scale bar, 8 μ m), *E* (scale bar, 5 μ m), and *F* (scale bar, 8 μ m). In *E* the GFP-expressing axons run parallel to the axis of many other axons running in the corpus callosum.

compared with the small granule cell neurons. The larger membrane area of the cell body of astrocytes compared with neurons would also contribute to the increased probability of viral infection. The more rapid expression of GFP in astrocytes than in neurons, coupled with the higher rate of replication in glia, is consistent with the concept that relative differences in viral infection exist.

Strong viral expression was found in radial glia in the developing mouse brain. One result of early CMV infection in human brains is the occurrence of microgyri (Diezel, 1954; Wolf and Cowen, 1972; Ho, 1991), a reduction in the size of cortical gyri. This has been previously attributed to vascular problems arising from CMV infection (Marques-Dias et al., 1984). However, we suggest another mechanism. Radial glia play an important role in




Figure 13. mCMV in neonatal mouse hippocampus. *A*, After intracerebral injection into the P2 mouse, cells surrounding the hippocampus show strong evidence of infection 3 d later. Scale bar, 45 μ m. *B*, Higher magnification of the same brain shows labeling of some dendritic arborizations (arrow) ventral to the pyramidal cell layer. Scale bar, 20 μ m.

serving as a pathway for the migration of neurons that are born in the ventricular zone and migrate outward along the radial glia in the developing rodent and primate brain (Rakic, 1978). Thus our data demonstrating CMV infection in radial glia in the developing brain suggest that after CMV-mediated radial glial degeneration, later outward neuronal migration may be blocked or misdirected. Thus microgyri or other anomalies of organization in CMV-infected human brains may hypothetically result from a selective loss of radial glia and subsequent abnormal neuronal migration. Further corroborating evidence is provided by studies in which mCMV was found to alter cortical neuronal migration in developing mice (Shinmura et al., 1997). Our finding of a high level of infection by mCMV in cells surrounding the hippocampus, with involvement of neurons within the hippocampus, may in some cases underlie hippocampal deficits, including epilepsy (Perez-Jimenez et al., 1998).

CMV may enter the brain in several ways. Our data showing CMV infection of the endothelial cells of the vascular system is consistent with a previous report suggesting that blockade of the vascular system may cause brain deficits (Marques-Dias et al., 1984; Wiley and Nelson, 1988). Another potential site of entry is

the olfactory mucosa. Olfactory ensheathing cells that surround the olfactory nerve as it penetrates the brain can be infected with CMV. After intraperitoneal infection with CMV, the virus was detected in cells of the olfactory mucosa (Trgovcich et al., 1998), and intranasal administration leads to viral infection (Mannini and Medearis, 1961). The olfactory mucosa to the olfactory bulb has been suggested as one route of entry into the CNS for a number of viruses, including polio virus, semliki forest virus, and vesicular stomatitis virus (Johnson, 1998). Experimental injection of CMV in the guinea pig (Booss et al., 1989) or mouse (Tsutsui et al., 1995) peritoneal cavity results in brain infection a few days later. The finding of infection of vascular endothelial cells suggests that mCMV could use these cells as a potential means of entering or exiting the neuropil of the brain. CMV-infected lymphocytes may provide a means of facilitating entry into the brain. Another possibility for viral penetration into the brain may be through neuronal axons. Axonal transport is a critical mode of viral translocation for some other virus such as polio, rabies, and herpes simplex-1 (Johnson, 1998). Transport of the virus through processes would serve as a partial explanation for the selective GFP expression in striatal neurons. It is unlikely that the promoters used expressed reporter genes in only one cell type, because in culture all brain cells showed GFP expression after virus addition to the culture medium.

Both *in vivo* and *in vitro* GFP-labeled axons showed severe dilations, and in culture, segments of labeled axons that had separated from the parent cell body. The lack of processes in later stages of infection of mouse neurons probably results from a combination of retraction of short processes and virally induced deterioration of the longer processes. Whether the virus may exert a direct and local effect on process deterioration or whether this process degeneration is secondary to infection in the cell body remains to be determined.

mCMV-mediated gene transfer

Although previous reports have suggested that mCMV does not infect human cells (Kim and Carp, 1971), by using the more sensitive recombinant mCMV described here we found robust GFP expression in human glial cells after infection. No obvious signs of cell death were found in mCMV-infected human cultures, suggesting that the mouse CMV may be a good candidate for further studies relating to use as a vector for gene introduction in human brain cells. A number of viruses, including herpes simplex-1, adenovirus, and adeno-associated virus, have been used for gene transfer in the CNS (Ho et al., 1995; Bartlett et al., 1998; Meier et al., 1998). Some viruses, for instance the Moloney murine leukemia retrovirus, may work well for gene transfer to dividing cells but work poorly in postmitotic neurons (Sena-Esteves et al., 1996). Although CMV has often provided its major immediate early gene promoter as a strong promoter of choice for expression of foreign genes in the brain, it has generally been adapted to other viruses such as adeno-associated virus (Lowenstein et al., 1996; Bartlett et al., 1998), and its expression from recombinant CMV has not been previously evaluated. The large size of the CMV genome can be an advantage or disadvantage. On the positive side, large inserts can be engineered into mCMV, unlike some other viruses such as adeno-associated virus, which has a size restriction of a few kilobases. On the other hand, the CMV genome codes for >200 proteins the expression of which might have consequences for the infected cell.




Figure 14. mCMV infects neurons of the rat brain. *A*, A medium-size spiny cell of the rat striatum is labeled 3 d after nearby mCMV administration and immunoperoxidase staining for GFP. Scale bar, 25 μ m. *B*, Higher magnification of *A* shows high density of dendritic spines (arrows) on labeled cell. *C*, Axon in the midbrain, from the same brain as *A–D*, shows labeling. Scale bar, 8 μ m. *D*, On an adjacent section to *A*, two more striatal neurons with their dendrites and axons show evidence of mCMV infection. Scale bar, 30 μ m. *E*, Neuron from cerebral cortex was infected with mCMV. Scale bar, 20 μ m.

Molecular deletions can remove viral genes that may prove deleterious to the use of these viruses as vectors (Saederup et al., 1999). Future experimentation using replication competent or defective mCMV or hCMV should examine these possibilities.

The fact that mCMV generated expression of GFP in neuronal cell bodies, dendrites, and axons suggests that these genetically engineered viruses may be useful as a tool for labeling neurons and their pathways. Labeled axons were found that extended thousands of micrometers away from perikarya near a zone of mCMV administration, indicating that GFP diffusion or transport is considerable. This is consistent with our previous work with transfection with plasmids coding for GFP under the regulation of the human major immediate early CMV promoter (van

den Pol et al., 1998) or in transgenic mice expressing GFP under the control of a human CMV promoter (van den Pol and Ghosh, 1998). Different sequences of the CMV promoter may result in reporter gene expression in different neurons of the CNS (Koepp et al., 1995; Baskar et al., 1996; Fritschy et al., 1996; van den Pol and Ghosh, 1998); differential activation of CMV promoters may serve as a partial explanation for why the virus may infect different regions of the brain and cause various neurological problems. With transgenic mice expressing reporter genes controlled by different regions of the immediate early promoter, neurons were commonly labeled, and labeled glia were rare; in contrast, in the present experiments we found that the mCMV retained the ability to express foreign genes in mouse, rat, and human glia and neurons.




Figure 15. Human brain cells are infected with mouse CMV. *A–C*, DIC, DIC + GFP, and GFP images of the same microscope field containing glial cells from a human astrocytoma are shown. A subset of cells shows strong GFP-mediated fluorescence. Scale bar, 10 μ m. *D, E*, The same field shows the DIC image (*D*) and the GFP image (*E*). A subset of human neuroblastoma cells, 2 d after plating with mCMV, is infected with virus. Scale bar, 10 μ m. *F*, “Normal” glial cells with an astrocyte morphology were cultured from human brain and show GFP expression 30 hr after infection. Scale bar, 10 μ m.

REFERENCES


- Alford CA, Britt WJ (1996) Cytomegalovirus. In: Fields virology (Fields BN, Knipe DM, Howley PM, eds), pp 2493–2534. New York: Lippincott-Raven.
- Arribas JR, Clifford DB, Fichtenbaum CJ, Commins DL, Powderly WG, Storch GA (1995) Level of cytomegalovirus (CMV) DNA in cerebrospinal fluid of subjects with AIDS and CMV infection of the central nervous system. *J Infect Dis* 172:527–531.
- Bale Jr JF, Bray PF, Bell WE (1985) Neuroradiographic abnormalities in congenital cytomegalovirus infection. *Pediatr Neurol* 1:42–47.
- Bartlett JS, Samulski RJ, McCown TJ (1998) Selective and rapid uptake of adeno-associated virus type 2 in brain. *Hum Gene Ther* 9:1181–1186.
- Baskar JF, Smith PP, Nilaver G, Jupp RA, Hoffmann S, Pepper NJ, Tenney DJ, Colberg-Poley AM, Ghazal P, Nelson JA (1996) The enhancer domain of the human cytomegalovirus major immediate-early promoter determines cell type-specific expression in transgenic mice. *J Virol* 70:3207–3214.
- Belec L, Gray F, Mikol J, Scaravelli F, Mhiri C, Sobel A, Poirier J (1990) Cytomegalovirus (CMV) encephalomyeloradiculitis and human immunodeficiency virus (HIV) encephalitis: presence of HIV

- and CMV co-infected multinucleated giant cells. *Acta Neuropathol* 81:99–104.
- Blomer U, Naldini L, Kafri T, Trono D, Verma IM, Gage FH (1997) Highly efficient and sustained gene transfer in adult neurons with a lentivirus vector. *J Virol* 71:6641–6649.
- Booss J, Dann PR, Griffith BP, Kim JH (1988) Glial nodule encephalitis in the guinea pig: serial observations following cytomegalovirus infection. *Acta Neuropathol* 75:465–473.
- Booss J, Winkler SR, Griffith BP, Kim JH (1989) Viremia and glial nodule encephalitis after experimental systemic cytomegalovirus infection. *Lab Invest* 61:644–649.
- Bray PF, Bale JF, Anderson RE, Kern ER (1981) Progressive neurological disease associated with chronic cytomegalovirus infection. *Ann Neurol* 9:499–502.
- Card JP, Rinaman L, Schwaber JS, Miselis RR, Whealy ME, Robbins AK, Enquist LW (1990) Neurotropic properties of pseudorabies virus: uptake and transneuronal passage in the rat central nervous system. *J Neurosci* 10:1974–1994.
- Card JP, Whealy ME, Robbins AK, Moore RY, Enquist LW (1991) Two alpha-herpesvirus strains are transported differentially in the rodent visual system. *Neuron* 6:957–969.
- Card JP, Enquist LW, Moore RY (1999) Neuroinvasiveness of pseudorabies virus injected intracerebrally is dependent on viral concentration and terminal field density. *J Comp Neurol* 407:438–452.
- Cardin RD, Abenes GB, Stoddart CA, Mocarski ES (1995) Murine cytomegalovirus IE2, an activator of gene expression, is dispensable for growth and latency in mice. *Virology* 209:236–241.
- Chimelli L, Rosenberg S, Hahn MD, Lopes MB, Netto MB (1992) Pathology of the central nervous system in patients infected with the human immunodeficiency virus (HIV): a report of 252 autopsy cases from Brazil. *Neuropathol Appl Neurobiol* 18:477–488.
- Dash R, Lawrence M, Ho D, Sapolsky R (1996) A herpes simplex virus vector overexpressing the glucose transporter gene protects the rat dentate gyrus from an antimetabolite toxin. *Exp Neurol* 137:43–48.
- Diezel PB (1954) Mikorgyrie infolge cerebraler Speicheldrusenvirus Infektion in Rahmen einer generalisierten Cytomegalie bei einem Saugling. Zugleich ein Beitrag zur Theorie der Windungsbildung. *Virchows Arch* 325:109–130.
- d'Arminio Monforte A, Vago L, Lazzarin A, Boldorini R, Bini T, Guzzetti S, Antinori S, Moroni M, Costanzi J (1992) AIDS-defining diseases in 250 HIV-infected patients: a comparative study of clinical and autopsy diagnoses. *AIDS* 6:1159–1164.
- Duclos H, Elfassi E, Michelson S, Arenzana Seisdedos F, Hazan U, Munier A, Virelizier JL (1989) Cytomegalovirus infection and transactivation of HIV-1 and HIV-2 LTRs in human astrocytoma cells. *AIDS Res Hum Retroviruses* 5:217–224.
- Fiala M, Singer EJ, Graves MC, Tourtellotte WW, Stewart JA, Schable CA, Rhodes RH, Vinters HV (1993) AIDS dementia complex complicated by cytomegalovirus encephalopathy. *J Neurol* 240:223–231.
- Fritschy JM, Brandner S, Aguzzi A, Koedood M, Luscher B, Mitchell PJ (1996) Brain cell type specificity and gliosis-induced activation of the human cytomegalovirus immediate-early promoter in transgenic mice. *J Neurosci* 16:2275–2282.
- Hicks T, Fowler K, Richardson M, Dahle A, Adams L, Pass R (1993) Congenital cytomegalovirus infection and neonatal auditory screening. *J Pediatr* 123:779–782.
- Ho DY, Fink SL, Lawrence MS, Meier TJ, Saydam TC, Dash R, Sapolsky RM (1995) Herpes simplex virus vector system: analysis of its in vivo and in vitro cytopathic effects. *J Neurosci Methods* 57:205–215.
- Ho KL, Gottlieb C, Zarbo RJ (1991) Cytomegalovirus infection of cerebral astrocytoma in an AIDS patient. *Clin Neuropathol* 10:127–133.
- Ho M (1991) Cytomegalovirus: biology and infection, Ed 2. New York: Plenum.
- Horn M, Schlote W, Herrman G, Gungor T, Jacobi G (1992) Immunocytochemical characterization of cytomegalovirus (CMV) infected giant cells in perinatal acquired human immunodeficiency virus (HIV) infection. *Acta Histochem [Suppl]* 42:115–122.
- Johansson CB, Momma S, Clarke DL, Risling M, Lendahl U, Frisen J (1999) Identification of a neural stem cell in the adult mammalian central nervous system. *Cell* 96:25–34.
- Johnson RT (1998) Viral infections of the nervous system. New York: Lippincott-Raven.
- Kalayjian RC, Cohen ML, Bonomo RA, Flanagan TP (1993) Cytomegalovirus ventriculoencephalitis in AIDS. A syndrome with distinct clinical and pathologic features. *Medicine (Baltimore)* 72:67–77.
- Kim KS, Carp RI (1971) Growth of cytomegalovirus in various cell lines. *J Virol* 7:720–725.
- Koedood M, Fichtel A, Meier P, Mitchell PJ (1995) Human cytomegalovirus (CMV) immediate-early enhancer/promoter specificity during embryogenesis defines target tissue of congenital HCMV infection. *J Virol* 69:2194–2207.
- Kosugi I, Shirmura Y, Li RY, Aiba-Masago S, Baba S, Miura K, Tsutsui Y (1998) Murine cytomegalovirus induces apoptosis in non-infected cells of the developing mouse brain and blocks apoptosis in primary neuronal culture. *Acta Neuropathol* 96:239–247.
- Liljelund P, Ghosh P, van den Pol AN (1994) Expression of the neural axon adhesion molecule L1 in the developing and adult rat brain. *J Biol Chem* 269:32886–32895.
- Lowenstein PR, Wilkinson GWG, Castro MG, Shering AF, Fooks AR, Bain D (1996) Non-neurotropic adenovirus: a vector for gene transfer to the brain and possible gene therapy of neurological disorders. In: Genetic manipulation of the nervous system (Lachman D, ed), pp 11–39. New York: Academic Press.
- Manning WC, Stoddart CA, Lagenaur LA, Abenes GB, Mocarski ES (1992) Cytomegalovirus determinant of replication in salivary glands. *J Virol* 66:3794–3802.
- Mannini A, Medearis DN (1961) Mouse salivary gland virus infections. *Am J Hygiene* 73:329–343.
- Marques-Dias MJ, Harmant-van Rijckevorsel G, Landrieu P, Lyon G (1984) Prenatal cytomegalovirus disease and cerebral microgyria: evidence for perfusion failure, not disturbance of histogenesis, as the major cause of fetal cytomegalovirus encephalopathy. *Neuropediatrics* 15:18–24.
- McCarthy M, Wood C, Fedoseyeva L, Whittemore SR (1995) Media components influence viral gene expression assays in human fetal astrocyte cultures. *J Neurovirol* 1:275–285.
- Meier TJ, Ho DY, Park TS, Sapolsky RM (1998) Gene transfer of calbindin D28k cDNA via herpes simplex virus amplicon vector decreases cytoplasmic calcium ion response and enhances neuronal survival following glutamatergic challenge but not following cyanide. *J Neurochem* 71:1013–1023.
- Miyoshi H, Takahashi M, Gage FH, Verma IM (1997) Stable and efficient gene transfer into the retina using an HIV-based lentiviral vector. *Proc Natl Acad Sci USA* 94:10319–10323.
- Mocarski E (1996) Cytomegaloviruses and their replication. In: Fields virology (Fields BN, Knipe DM, Howley PM, eds), pp 2447–2492. New York: Lippincott-Raven.
- Myerson D, Hackman RC, Nelson JA, Ward DC, McDougall JK (1984) Widespread presence of histologically occult cytomegalovirus. *Hum Pathol* 15:430–439.
- Navia BA, Cho ES, Petito CK, Price RW (1986) The AIDS dementia complex: II. Neuropathology. *Ann Neurol* 19:525–535.
- Nelson JA, Reynolds-Kohler C, Oldstone MBA, Wiley CA (1988) HIV and HCMV coinfect brain cells in patients with AIDS. *Virology* 165:286–290.
- Osborn JE (1982) Cytomegalovirus and other herpesviruses. In: The mouse in biomedical research. II. Diseases. (Foster HL, Small JD, Fox JG, eds), pp 267–292. New York: Academic.
- Perez-Jimenez A, Colamaria V, Franco A, Grima-Merino R, Darra R, Fontana E, Zullini E, Beltramello A, Dalla-Bernardina B (1998) Epilepsy and disorders of cortical development in children with congenital cytomegalovirus infection. *Rev Neurol* 26:42–49.
- Pulliam L (1991) Cytomegalovirus preferentially infects a monocyte derived macrophage/microglial cell in human brain cultures: neuropathology differs between strains. *J Neuropathol Exp Neurol* 50:432–440.
- Rakic P (1978) Neuronal migration and contact guidance in the primate telencephalon. *Postgrad Med J [Suppl 54]* 1:25–40.
- Rawlinson WD, Farrell HE, Barrell BG (1996) Analysis of the complete DNA sequence of murine cytomegalovirus. *J Virol* 70:8833–8849.
- Ramon-Cueto A, Valverde F (1995) Olfactory bulb ensheathing glia: a unique cell type with axonal growth-promoting properties. *Glia* 14:163–173.
- Robinson AP, White TM, Mason DW (1986) Macrophage heterogeneity in the rat as delineated by two monoclonal antibodies MRC OX-41 and MRC OX-42, the latter recognizing complement receptor type 3. *Immunology* 57:239–247.
- Saederup N, Lin YC, Dairaghi DJ, Schall TJ, Mocarski ES (1999) Cytomegalovirus-encoded beta chemokine promotes monocyte-

- associated viremia in the host. *Proc Natl Acad Sci USA* 96:10881–10886.
- Sena-Esteves M, Aghi M, Pechan PA, Kaye EM, Breakefield XO (1996) Gene delivery to the nervous system using retroviral vectors. In: *Genetic manipulation of the nervous system* (Lachman D, ed), pp 149–180. New York: Academic Press.
- Shinmura Y, Kosugi I, Aiba-Masago S, Baba S, Yong LR, Tsutsui Y (1997) Disordered migration and loss of virus-infected neuronal cells in developing mouse brains infected with murine cytomegalovirus. *Acta Neuropathol (Berl)* 93:551–557.
- Slobedman B, Mocarski ES (1999) Quantitative analysis of latent human cytomegalovirus. *J Virol* 73:4806–4812.
- Trgovcich J, Pernjak-Pugel E, Tomac J, Koszinowski UH, Jonjic S (1998) Pathogenesis of murine cytomegalovirus infection in neonatal mice. In: *CMV related immunopathology* (Scholz M, Rabenau HF, Doerr HW, Cinatl J, eds), pp 42–53. Basel: Karger.
- Tsutsui Y (1995) Developmental disorders of the mouse brain induced by murine cytomegalovirus: animal models for congenital cytomegalovirus infection. *Pathol Int* 45:91–102.
- Tsutsui Y, Kashiwai A, Kawamura N, Aiba-Masago SA, Kosugi I (1995) Prolonged infection of mouse brain neurons with murine cytomegalovirus after pre- and perinatal infection. *Acta Virol* 140:1725–1736.
- Uetsuki T, Naito A, Nagata S, Kaziro Y (1989) Isolation and characterization of the human chromosomal gene for polypeptide chain elongation factor-1 alpha. *J Biol Chem* 264:5791–5798.
- van den Pol AN, Ghosh PK (1998) Selective neuronal expression of green fluorescent protein with cytomegalovirus promoter reveals entire neuronal arbor in transgenic mice. *J Neurosci* 18:10640–10651.
- van den Pol AN, Kim WT (1993) NILE/L1 and NCAM-polysialic acid expression on growing axons of isolated neurons. *J Comp Neurol* 332:237–257.
- van den Pol AN, Finkbeiner SM, Cornell-Bell AH (1992) Calcium excitability and oscillations in suprachiasmatic nucleus neurons and glia in vitro. *J Neurosci* 12:2648–2664.
- van den Pol AN, Obrietan K, Belousov AB, Yang Y, Heller HC (1998) Early synaptogenesis in vitro: role of axon target distance. *J Comp Neurol* 399:541–560.
- van der Hoff MJ, Moorman AF, Lamers WF (1992) Electroporation in “intracellular” buffer increases cell survival. *Nucleic Acids Res* 20:2902.
- Vickland H, Westrum LE, Kott JN, Patterson SL, Bothwell MA (1991) Nerve growth factor receptor expression in the young and adult rat olfactory system. *Brain Res* 565:269–279.
- Vieira J, Farrell HE, Rawlinson WD, Mocarski ES (1994) Genes in the HindIII J fragment of the murine cytomegalovirus genome are dispensable for growth in cultured cells: insertion mutagenesis with a lacZ/gpt cassette. *J Virol* 68:4837–4846.
- White DO, Fenner FJ (1994) *Medical virology*. New York: Academic.
- Wiley CA, Nelson JA (1988) Role of human immunodeficiency virus and cytomegalovirus in AIDS encephalitis. *Am J Pathol* 133:73–81.
- Wiley CA, Schrier RD, Denaro FJ, Nelson JA, Lampert PW, Oldstone MB (1986) Localization of cytomegalovirus proteins and genome during fulminant central nervous system infection in an AIDS patient. *J Neuropathol Exp Neurol* 45:127–139.
- Wolf A, Cowen D (1972) Perinatal infections of the central nervous system. In: *Pathology of the nervous system* (Minckler J, ed), pp 2565–2611. New York: McGraw-Hill.

Merck Index, 12th Edition

6222. Metitepine. 1-[10,11-Dihydro-8-(methylthio)di-benzo[b,f]thiepin-10-yl]-4-methylpiperazine; 8-methylthio-10-(4-methylpiperazino)-10,11-dihydrodibenzo[b,f]thiepine; methiothepine; methiothepin; Ro-8-6837. $C_{20}H_{24}N_2S_2$; mol wt 356.56. C 67.37%, H 6.78%, N 7.86%, S 17.99%. Serotonin (5-HT₂) receptor antagonist; also exhibits affinity for 5-HT₁-receptors. Prepn: Neth. pat. Appl. 6,608,618; M. Protiva *et al.* U.S. pat. 3,379,729 (1966, 1968 both to SPOFA); and pharmacology: K. Pelz *et al.*, *Coll. Czech. Chem. Commun.* 33, 1895 (1968); J. O. Jilek *et al.*, *ibid.* 39, 3338 (1974). Receptor-blocking study: M.-A. Monachon *et al.*, *Arch. Pharmacol.* 274, 192 (1972). Use in classification of 5-HT receptors: P. B. Bradley *et al.*, *Neuropharmacology* 25, 563 (1986); E. J. Mylecharane, *Clin. Exp. Pharmacol. Physiol.* 16, 517 (1989).



Crystals from ethanol, mp 88-89°. Maleate, $C_{20}H_{24}N_2S_2 \cdot C_4H_4O_4$, crystals from ethanol, mp 171-173°. LD₅₀ in mice (mg/kg): 51 i.v.; 94 orally (Jilek).
USE: Biochemical tool in serotonin receptor binding studies.

Sigma - RBI Catalog 1999


Octoclothepin maleate

25 mg	29.00
100 mg	85.00

D₂ Dopamine receptor antagonist; serotonin receptor antagonist.

1-(8-Chloro-10,11-dihydrodibenzo[b,f]thiepin-10-yl)-4-methyl-piperazine maleate
Mol. Wt. 460.98 $C_{19}H_{21}ClN_2S \cdot C_4H_4O_4$ [4789-68-8] Disposal A. White solid; mp 203-204°C. Store tightly sealed at RT. Slightly soluble in water or methanol. Solubility in 45% (w/v) aqueous 2-hydroxypropyl-β-cyclodextrin (Cat. No. H-107): > 21 mg/ml.

Hyttel *et al.* "Characterization of binding of ³H-SCH 23390 to dopamine D₁ receptors. Correlation to other D-1 and D-2 measures and effect of selective lesions." *J. Neural Trans.* 68, 171 (1987); Nakajima *et al.* "[³H]Ro 22-1319 (piquindone) binds to the D₂ dopaminergic receptor subtype in a sodium-dependent manner." *Mol. Pharmacol.* 26, 430 (1984); Wang Lu *et al.* "Effects of various neuroleptics, phenobarbital and SKF 525-A on dimethyltryptamine content in rat brain and liver." *Arch. Int. Pharmacodyn. Ther.* 232, 117 (1978).



Methiothepin mesylate


Metitepine mesylate

100 mg	40.00
250 mg	81.00

5-HT₁ Serotonin receptor antagonist; blocks serotonin autoreceptors.

1-[10,11-Dihydro-8-(methylthio)dibenzo[b,f]thiepin-10-yl]-4-methylpiperazine mesylate
Mol. Wt. 452.64 $C_{20}H_{24}N_2S_2 \cdot CH_3SO_3H$ [20229-30-5 (free base)] Disposal A. White solid; mp 188-190°C. Store tightly sealed at RT. Soluble in water (13 mg/ml).

Martin *et al.* "Comparison of the pharmacological characteristics of 5HT₁ and 5HT₂ binding sites with those of serotonin autoreceptors which modulate serotonin release." *Naunyn-Schmiedeberg's Arch. Pharmacol.* 321, 165-170 (1982); Nelson *et al.* "In vitro and in vivo disposition of [³H]-Methiothepin in brain tissues." *Ibid* 310, 25-33 (1979); Pettibone *et al.* "Effects of methiothepin and lysergic acid diethylamide on serotonin release in vitro and serotonin synthesis in vivo: Possible relation to serotonin autoreceptor function." *J. Neurochem.* 43, 83-90 (1984).



Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions

JAMES U. BOWIE,* JOHN F. REIDHAAR-OLSON, WENDELL A. LIM,
ROBERT T. SAUER

An amino acid sequence encodes a message that determines the shape and function of a protein. This message is highly degenerate in that many different sequences can code for proteins with essentially the same structure and activity. Comparison of different sequences with similar messages can reveal key features of the code and improve understanding of how a protein folds and how it performs its function.

THE GENOME IS MANIFEST LARGELY IN THE SET OF PROTEINS that it encodes. It is the ability of these proteins to fold into unique three-dimensional structures that allows them to function and carry out the instructions of the genome. Thus, comprehending the rules that relate amino acid sequence to structure is fundamental to an understanding of biological processes. Because an amino acid sequence contains all of the information necessary to determine the structure of a protein (1), it should be possible to predict structure from sequence, and subsequently to infer detailed aspects of function from the structure. However, both problems are extremely complex, and it seems unlikely that either will be solved in an exact manner in the near future. It may be possible to obtain approximate solutions by using experimental data to simplify the problem. In this article, we describe how an analysis of allowed amino acid substitutions in proteins can be used to reduce the complexity of sequences and reveal important aspects of structure and function.

Methods for Studying Tolerance to Sequence Variation

There are two main approaches to studying the tolerance of an amino acid sequence to change. The first method relies on the process of evolution, in which mutations are either accepted or rejected by natural selection. This method has been extremely powerful for proteins such as the globins or cytochromes, for which sequences from many different species are known (2-7). The second approach uses genetic methods to introduce amino acid changes at

specific positions in a cloned gene and uses selections or screens to identify functional sequences. This approach has been used to great advantage for proteins that can be expressed in bacteria or yeast, where the appropriate genetic manipulations are possible (3, 8-11). The end results of both methods are lists of active sequences that can be compared and analyzed to identify sequence features that are essential for folding or function. If a particular property of a side chain, such as charge or size, is important at a given position, only side chains that have the required property will be allowed. Conversely, if the chemical identity of the side chain is unimportant, then many different substitutions will be permitted.

Studies in which these methods were used have revealed that proteins are surprisingly tolerant of amino acid substitutions (2-4, 11). For example, in studying the effects of approximately 1500 single amino acid substitutions at 142 positions in *lac* repressor, Miller and co-workers found that about one-half of all substitutions were phenotypically silent (11). At some positions, many different, nonconservative substitutions were allowed. Such residue positions play little or no role in structure and function. At other positions, no substitutions or only conservative substitutions were allowed. These residues are the most important for *lac* repressor activity.

What roles do invariant and conserved side chains play in proteins? Residues that are directly involved in protein functions such as binding or catalysis will certainly be among the most conserved. For example, replacing the Asp in the catalytic triad of trypsin with Asn results in a 10^4 -fold reduction in activity (12). A similar loss of activity occurs in λ repressor when a DNA binding residue is changed from Asn to Asp (13). To carry out their function, however, these catalytic residues and binding residues must be precisely oriented in three dimensions. Consequently, mutations in residues that are required for structure formation or stability can also have dramatic effects on activity (10, 14-16). Hence, many of the residues that are conserved in sets of related sequences play structural roles.


Substitutions at Surface and Buried Positions

In their initial comparisons of the globin sequences, Perutz and co-workers found that most buried residues require nonpolar side chains, whereas few features of surface side chains are generally conserved (6). Similar results have been seen for a number of protein families (2, 4, 5, 7, 17, 18). An example of the sequence tolerance at surface versus buried sites can be seen in Fig. 1, which shows the allowed substitutions in λ repressor at residue positions that are near the dimer interface but distant from the DNA binding surface of the protein (9). These substitutions were identified by a functional

The authors are in the Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139.

*Present address: Department of Chemistry and Biochemistry and the Molecular Biology Institute, University of California, Los Angeles, Los Angeles, CA 90024.

Fig. 1. (A) Amino acid substitutions allowed in a short region of λ repressor. The wild-type sequence is shown along the center line. The allowed substitutions shown above each position were identified by randomly mutating one to three codons at a time by using a cassette method and applying a functional selection (9). **(B)** The fractional solvent accessibility (42) of the wild-type side chain in the protein dimer (43) relative to the same atoms in an Ala-X-Ala model tripeptide.



selection after cassette mutagenesis. A histogram of side chain solvent accessibility in the crystal structure of the dimer is also shown in Fig. 1. At six positions, only the wild-type residue or relatively conservative substitutions are allowed. Five of these positions are buried in the protein. In contrast, most of the highly exposed positions tolerate a wide range of chemically different side chains, including hydrophilic and hydrophobic residues. Hence, it seems that most of the structural information in this region of the protein is carried by the residues that are solvent inaccessible.

Constraints on Core Sequences

Because core residue positions appear to be extremely important for protein folding or stability, we must understand the factors that dictate whether a given core sequence will be acceptable. In general, only hydrophobic or neutral residues are tolerated at buried sites in proteins, undoubtedly because of the large favorable contribution of the hydrophobic effect to protein stability (19). For example, Fig. 2 shows the results of genetic studies used to investigate the substitutions allowed at residue positions that form the hydrophobic core of the NH₂-terminal domain of λ repressor (20). The acceptable core sequences are composed almost exclusively of Ala, Cys, Thr, Val, Ile, Leu, Met, and Phe. The acceptability of many different residues at each core position presumably reflects the fact that the hydrophobic effect, unlike hydrogen bonding, does not depend on specific residue pairings. Although it is possible to imagine a hypothetical core structure that is stabilized exclusively by residues forming hydrogen bonds and salt bridges, such a core would probably be difficult to construct because hydrogen bonds require pairing of donors and acceptors in an exact geometry. Thus the repertoire of possible structures that use a polar core would probably be extremely limited (21). Polar and charged residues are occasionally found in the cores of proteins, but only at positions where their hydrogen bonding needs can be satisfied (22).


The cores of most proteins are quite closely packed (23), but some volume changes are acceptable. In λ repressor, the overall core volume of acceptable sequences can vary by about 10%. Changes at individual sites, however, can be considerably larger. For example, as shown in Fig. 2, both Phe and Ala are allowed at the same core position in the appropriate sequence contexts. Large volume changes at individual buried sites have also been observed in

phylogenetic studies, where it has been noted that the size decreases and increases at interacting residues are not necessarily related in a simple complementary fashion (5, 7, 17). Rather, local volume changes are accommodated by conformational changes in nearby side chains and by a variety of backbone movements.

The Informational Importance of the Core

With occasional exceptions, the core must remain hydrophobic and maintain a reasonable packing density. However, since the core is composed of side chains that can assume only a limited number of conformations (24), efficient packing must be maintained without steric clashes. How important are hydrophobicity, volume, and steric complementarity in determining whether a given sequence can form an acceptable core? Each factor is essential in a physical sense, as a stable core is probably unable to tolerate unsatisfied hydrogen bonding groups, large holes, or steric overlaps (25). However, in an informational sense, these factors are not equivalent. For example, in experiments in which three core residues of λ repressor were mutated simultaneously, volume was a relatively unimportant informational constraint because three-quarters of all possible combinations of the 20 naturally occurring amino acids had volumes within the range tolerated in the core, and yet most of these sequences were unacceptable (20). In contrast, of the sequences that contained only

Fig. 2. Amino acid substitutions allowed in the core of λ repressor. The wild-type side chains are shown pictorially in the approximate orientation seen in the crystal structure (43). The lists of allowed substitutions at each position are shown below the wild-type side chains. These substitutions were identified by randomly mutating one to four residues at a time by using a cassette method and applying a functional selection (20). Not all substitutions are allowed in every sequence background.



the appropriate hydrophobic residues, a significant fraction were acceptable. Hence, the hydrophobicity of a sequence contains more information about its potential acceptability in the core than does the total side chain volume. Steric compatibility was intermediate between volume and hydrophobicity in informational importance.

The Informational Importance of Surface Sites

We have noted that many surface sites can tolerate a wide variety of side chains, including hydrophilic and hydrophobic residues. This result might be taken to indicate that surface positions contain little structural information. However, Bashford *et al.*, in an extensive analysis of globin sequences (4), found a strong bias against large hydrophobic residues at many surface positions. At one level, this may reflect constraints imposed by protein solubility, because large patches of hydrophobic surface residues would presumably lead to aggregation. At a more fundamental level, protein folding requires a partitioning between surface and buried positions. Consequently, to achieve a unique native state without significant competition from other conformations, it may be important that some sites have a decided preference for exterior rather than interior positions. As a result, many surface sites can accept hydrophobic residues individually, but the surface as a whole can probably tolerate only a moderate number of hydrophobic side chains.

Identification of Residue Roles from Sets of Sequences

Often, a protein of interest is a member of a family of related sequences. What can we infer from the pattern of allowed substitutions at positions in sets of aligned sequences generated by genetic or phylogenetic methods? Residue positions that can accept a number of different side chains, including charged and highly polar residues, are almost certain to be on the protein surface. Residue positions that remain hydrophobic, whether variable or not, are likely to be buried within the structure. In Fig. 3, those residue positions in λ repressor that can accept hydrophilic side chains are shown in orange and those that cannot accept hydrophilic side chains are shown in green. The obligate hydrophobic positions define the core of the structure, whereas positions that can accept hydrophilic side chains define the surface.

Functionally important residues should be conserved in sets of active sequences, but it is not possible to decide whether a side chain is functionally or structurally important just because it is invariant or conserved. To make this distinction requires an independent assay of protein folding. The ability of a mutant protein to maintain a stably folded structure can often be measured by biophysical techniques, by susceptibility to intracellular proteolysis (26), or by binding to antibodies specific for the native structure (27, 28). In the latter cases, it is possible to screen proteins in mutated clones for the ability to fold even if these proteins are inactive. Sets of sequences that allow formation of a stable structure can then be compared to the sets that allow both folding and function, with the active site or binding residues being those that are variable in the set of stable proteins but invariant in the set of functional proteins. The DNA-binding residues of Arc repressor were identified by this method (8). The receptor-binding residues of human growth hormone were also identified by comparing the stabilities and activities of a set of mutant sequences (28). However, in this case, the mutants were generated as hybrid sequences between growth hormone and related hormones with different binding specificities.

Implications for Structure Prediction

At present, the only reliable method for predicting a low-resolution tertiary structure of a new protein is by identifying sequence similarity to a protein whose structure is already known (29, 30). However, it is often difficult to align sequences as the level of sequence similarity decreases, and it is sometimes impossible to detect statistically significant sequence similarity between distantly related proteins. Because the number of known sequences is far greater than the number of known structures, it would be advantageous to increase the reach of the available structural information by improving methods for detecting distant sequence relations and for subsequently aligning these sequences based on structural principles. In a normal homology search, the sequence database is scanned with a single test sequence, and every residue must be weighted equally. However, some residues are more important than others and should be weighted accordingly. Moreover, certain regions of the protein are more likely to contain gaps than others. Both kinds of information can be obtained from sequence sets, and several techniques have




Fig. 3. Tolerance of positions in the NH₂-terminal domain of λ repressor to hydrophilic side chains. The complex (43) of the repressor dimer (blue) and operator DNA (white) is shown. In (A), positions that can tolerate hydrophilic side chains are shown in orange. The same side chains are shown in (B) without the remaining protein atoms. In (C), positions that require hydrophobic or neutral side chains are shown in green. These side chains are shown in (D) without the remaining protein atoms. About three-fourths of the 92 side chains in the NH₂-terminal domain are included in both (B) and (D). The remaining positions have not been tested. Data are from (9, 14, 20, 27, 44).

been used to combine such information into more appropriately weighted sequence searches and alignments (31). These methods were used to align the sequences of retroviral proteases with aspartic proteases, which in turn allowed construction of a three-dimensional model for the protease of human immunodeficiency virus type 1 (29). Comparison with the recently determined crystal structure of this protein revealed reasonable agreement in many areas of the predicted structure (32).

The structural information at most surface sites is highly degenerate. Except for functionally important residues, exterior positions seem to be important chiefly in maintaining a reasonably polar surface. The information contained in buried residues is also degenerate, the main requirement being that these residues remain hydrophobic. Thus, at its most basic level, the key structural message in an amino acid sequence may reside in its specific pattern of hydrophobic and hydrophilic residues. This is meant in an informational sense. Clearly, the precise structure and stability of a protein depends on a large number of detailed interactions. It is possible, however, that structural prediction at a more primitive level can be accomplished by concentrating on the most basic informational aspects of an amino acid sequence. For example, amphipathic patterns can be extracted from aligned sets of sequences and used, in some cases, to identify secondary structures.

If a region of secondary structure is packed against the hydrophobic core, a pattern of hydrophobic residues reflecting the periodicity of the secondary structure is expected (33, 34). These patterns can be obscured in individual sequences by hydrophobic residues on the protein surface. It is rare, however, for a surface position to remain hydrophobic over the course of evolution. Consequently, the amphipathic patterns expected for simple secondary structures can be much clearer in a set of related sequences (6). This principle is illustrated in Fig. 4, which shows helical hydrophobic moment plots for the Antennapedia homeodomain sequence (Fig. 4A) and for a composite sequence derived from a set of homologous homeodomain proteins (Fig. 4B) (35). The hydrophobic moment is a simple measure of the degree of amphipathic character of a sequence in a given secondary structure (34). The amphipathic character of the three α -helical regions in the Antennapedia protein (36) is clearly revealed only by the analysis of the combined set of homeodomain sequences. The secondary structure of Arc repressor, a small DNA-binding protein, was recently predicted by a similar method (8) and confirmed by nuclear magnetic resonance studies (37).

The specific pattern of hydrophobic and hydrophilic residues in an amino acid sequence must limit the number of different structures a given sequence can adopt and may indeed define its overall fold. If this is true, then the arrangement of hydrophobic and hydrophilic residues should be a characteristic feature of a particular fold. Sweet and Eisenberg have shown that the correlation of the pattern of hydrophobicity between two protein sequences is a good criterion for their structural relatedness (38). In addition, several studies indicate that patterns of obligatory hydrophobic positions identified from aligned sequences are distinctive features of sequences that adopt the same structure (4, 29, 38, 39). Thus, the order of hydrophobic and hydrophilic residues in a sequence may actually be sufficient information to determine the basic folding pattern of a protein sequence.

Although the pattern of sequence hydrophobicity may be a characteristic feature of a particular fold, it is not yet clear how such patterns could be used for prediction of structure *de novo*. It is important to understand how patterns in sequence space can be related to structures in conformation space. Lau and Dill have approached this problem by studying the properties of simple sequences composed only of H (hydrophobic) and P (polar) groups on two-dimensional lattices (40). An example of such a representa-

tion is shown in Fig. 5. Residues adjacent in the sequence must occupy adjacent squares on the lattice, and two residues cannot occupy the same space. Free energies of particular conformations are evaluated with a single term, an attraction of H groups. By considering chains of ten residues, an exhaustive conformational search for all 1024 possible sequences of H and P residues was possible. For longer sequences only a representative fraction of the allowed sequence or conformation space could be explored. The significant results were as follows: (i) not all sequences can fold into a "native" structure and only a few sequences form a unique native structure; (ii) the probability that a sequence will adopt a unique native structure increases with chain length; and (iii) the native states are compact, contain a hydrophobic core surrounded by polar residues, and contain significant secondary structure. Although the gap between these two-dimensional simulations and three-dimensional structures is large, the use of simple rules and sequence representations yields results similar to those expected for real proteins. Three-dimensional lattice methods are also beginning to be developed and evaluated (41).

Summary

There is more information in a set of related sequences than in a single sequence. A number of practical applications arise from an analysis of the tolerance of residue positions to change. First, such information permits the evaluation of a residue's importance to the function and stability of a protein. This ability to identify the essential elements of a protein sequence may improve our understanding of the determinants of protein folding and stability as well as protein function. Second, patterns of tolerance to amino acid substitutions of varying hydrophilicity can help to identify residues likely to be buried in a protein structure and those likely to occupy




Fig. 4. Helical hydrophobic moments calculated by using (A) the Antennapedia homeodomain sequence or (B) a set of 39 aligned homeodomain sequences (35). The bars indicate the extent of the helical regions identified in nuclear magnetic resonance studies of the Antennapedia homeodomain (36). To determine hydrophobic moments, residues were assigned to one of three groups: H1 (high hydrophobicity = Trp, Ile, Phe, Leu, Met, Val, or Cys); H2 (medium hydrophobicity = Tyr, Pro, Ala, Thr, His, Gly, or Ser); and H3 (low hydrophobicity = Gln, Asn, Glu, Asp, Lys, or Arg). For the aligned homeodomain sequences, the residues at each position were sorted by their hydrophobicity by using the scale of Fauchere and Pliska (45). Arg and Lys were not counted unless no other residue was found at the position, because they contain long aliphatic side chains and can thereby substitute for nonpolar residues at some buried sites. To account for possible sequence errors and rare exceptions, the most hydrophilic residue allowed at each position was discarded unless it was observed twice. The second most hydrophilic residue was then chosen to represent the hydrophobicity of each position. An eight-residue window was used and the vectors projected radially every 100°. The vector magnitudes were assigned a value of 1, 0, or -1 for positions where the hydrophobicity group was H1, H2, or H3, respectively.

P H P P H P H P H H P P H




Fig. 5. A representation of one compact conformation for a particular sequence of H and P residues on a two-dimensional square lattice. [Adapted from (40), with permission of the American Chemical Society]

surface positions. The amphipathic patterns that emerge can be used to identify probable regions of secondary structure. Third, incorporating a knowledge of allowed substitutions can improve the ability to detect and align distantly related proteins because the essential residues can be given prominence in the alignment scoring.

As more sequences are determined, it becomes increasingly likely that a protein of interest is a member of a family of related sequences. If this is not the case, it is now possible to use genetic methods to generate lists of allowed amino acid substitutions. Consequently, at least in the short term, it may not be necessary to solve the folding problem for individual protein sequences. Instead, information from sequence sets could be used. Perhaps by simplifying sequence space through the identification of key residues, and by simplifying conformation space as in the lattice methods, it will be possible to develop algorithms to generate a limited number of trial structures. These trial structures could then, in turn, be evaluated by further experiments and more sophisticated energy calculations.

REFERENCES AND NOTES

1. C. J. Epstein, R. F. Goldberger, C. B. Anfinsen, *Cold Spring Harbor Symp. Quant. Biol.* **28**, 439 (1963); C. B. Anfinsen, *Science* **181**, 223 (1973).
2. R. E. Dickerson, *Sci. Am.* **242**, 136 (March 1980).
3. M. D. Hampsey, G. Das, F. Sherman, *FEBS Lett.* **231**, 275 (1988).
4. D. Bashford, C. Chothia, A. M. Lesk, *J. Mol. Biol.* **196**, 199 (1987).
5. A. M. Lesk and C. Chothia, *ibid.* **136**, 225 (1980).
6. M. F. Perutz, J. C. Kendrew, H. C. Watson, *ibid.* **13**, 669 (1965).
7. C. Chothia and A. M. Lesk, *Cold Spring Harbor Symp. Quant. Biol.* **52**, 399 (1987).
8. J. U. Bowie and R. T. Sauer, *Proc. Natl. Acad. Sci. U.S.A.* **86**, 2152 (1989).
9. J. F. Reidhaar-Olson and R. T. Sauer, *Science* **241**, 53 (1988); *Protein Struct. Funct. Genet.*, in press.
10. D. Shortle, *J. Biol. Chem.* **264**, 5315 (1989).
11. J. H. Miller et al., *J. Mol. Biol.* **131**, 191 (1979).
12. S. Sprang et al., *Science* **237**, 905 (1987); C. S. Craik, S. Rocznik, C. Largman, W. J. Rutter, *ibid.*, p. 909.
13. H. C. M. Nelson and R. T. Sauer, *J. Mol. Biol.* **192**, 27 (1986).
14. M. H. Hecht, J. M. Sturtevant, R. T. Sauer, *Proc. Natl. Acad. Sci. U.S.A.* **81**, 5685 (1984).
15. T. Alber, D. Sun, J. A. Nye, D. C. Muchmore, B. W. Matthews, *Biochemistry* **26**, 3754 (1987).
16. D. Shortle and A. K. Meeker, *Protein Struct. Funct. Genet.* **1**, 81 (1986).
17. A. M. Lesk and C. Chothia, *J. Mol. Biol.* **160**, 325 (1982).
18. W. R. Taylor, *ibid.* **188**, 233 (1986).
19. W. Kauzmann, *Adv. Protein Chem.* **14**, 1 (1959); R. L. Baldwin, *Proc. Natl. Acad. Sci. U.S.A.* **83**, 8069 (1986).
20. W. A. Lim and R. T. Sauer, *Nature* **339**, 31 (1989); in preparation.
21. Lesk and Chothia (5) have argued that a protein core composed solely of hydrogen-bonded residues would also be inviable on evolutionary grounds, as a mutational change in one core residue would require compensating changes in any interacting residue or residues to maintain a stable structure.
22. T. M. Gray and B. W. Matthews, *J. Mol. Biol.* **175**, 75 (1984); E. N. Baker and R. E. Hubbard, *Prog. Biophys. Mol. Biol.* **44**, 97 (1984).
23. F. M. Richards, *J. Mol. Biol.* **82**, 1 (1974).
24. J. W. Ponder and F. M. Richards, *ibid.* **193**, 775 (1987).
25. J. T. Kellis, Jr., K. Nyberg, A. R. Fersht, *Biochemistry* **28**, 4914 (1989); W. S. Sandberg and T. C. Terwilliger, *Science* **245**, 54 (1989).
26. A. A. Pakula and R. T. Sauer, *Protein Struct. Funct. Genet.* **5**, 202 (1989).
27. B. C. Cunningham and J. A. Wells, *Science* **244**, 1081 (1989); R. M. Breyer and R. T. Sauer, *J. Biol. Chem.* **264**, 13348 (1989).
28. B. C. Cunningham, P. Jhurani, P. Ng, J. A. Wells, *Science* **243**, 1330 (1989).
29. L. H. Pearl and W. R. Taylor, *Nature* **329**, 351 (1987).
30. W. J. Brown et al., *J. Mol. Biol.* **42**, 65 (1969); J. Greer, *ibid.* **153**, 1027 (1981); J. M. Berg, *Proc. Natl. Acad. Sci. U.S.A.* **85**, 99 (1988).
31. W. R. Taylor, *Protein Eng.* **2**, 77 (1988).
32. M. A. Navia et al., *Nature* **337**, 615 (1989).
33. M. Schiffer and A. B. Edmundson, *Biophys. J.* **7**, 121 (1967); V. I. Lim, *J. Mol. Biol.* **88**, 857 (1974); *ibid.*, p. 873.
34. D. Eisenberg, R. M. Weiss, T. C. Terwilliger, *Nature* **299**, 371 (1982); D. Eisenberg, D. Schwarz, M. Komaromy, R. Wall, *J. Mol. Biol.* **179**, 125 (1984); D. Eisenberg, R. M. Weiss, T. C. Terwilliger, *Proc. Natl. Acad. Sci. U.S.A.* **81**, 140 (1984).
35. T. R. Burglin, *Cell* **53**, 339 (1988).
36. G. Otting et al., *EMBO J.* **7**, 4305 (1988).
37. J. N. Breg, R. Boelens, A. V. E. George, R. Kaptein, *Biochemistry* **28**, 9826 (1989); M. G. Zagorski, J. U. Bowie, A. K. Vershon, R. T. Sauer, D. J. Patel, *ibid.*, p. 9813.
38. R. M. Sweet and D. Eisenberg, *J. Mol. Biol.* **171**, 479 (1983).
39. J. U. Bowie, N. D. Clarke, C. O. Pabo, R. T. Sauer, *Protein Struct. Funct. Genet.*, in preparation.
40. K. F. Lau and K. A. Dill, *Macromolecules* **22**, 3986 (1989).
41. A. Sikorski and J. Skolnick, *Proc. Natl. Acad. Sci. U.S.A.* **86**, 2668 (1989); A. Kolinski, J. Skolnick, R. Yaris, *Biopolymers* **26**, 937 (1987); D. G. Covell and R. L. Jernigan, *Biochemistry*, in press.
42. B. Lee and F. M. Richards, *J. Mol. Biol.* **55**, 379 (1971).
43. S. R. Jordan and C. O. Pabo, *Science* **242**, 893 (1988).
44. R. M. Breyer, thesis, Massachusetts Institute of Technology, Cambridge (1988).
45. J.-L. Fauchere and V. Pliska, *Eur. J. Med. Chem.-Chim. Ther.* **18**, 369 (1983).
46. We thank C. O. Pabo and S. Jordan for coordinates of the NH₂-terminal domain of λ repressor and its operator complex. We also thank P. Schimmel for the use of his graphics system and J. Burnbaum and C. Francklyn for assistance. Supported in part by NIH grant AI-15706 and predoctoral grants from NSF (J.R.-O.) and Howard Hughes Medical Institute (W.A.L.).

1271 *This Week in Science*

Editorial

- 1273 Support for Materials Science and Engineering

Letters

- 1280 U.S. Oil and Gas Consumption: Is Another Crisis Ahead?: D. B. HAWKINS;
R. L. HIRSCH ■ Punitive Damages and Innovation: D. H. KAYE; A. BROWN;
R. L. RANDALL; R. J. MAHONEY AND S. E. LITTLEJOHN

News & Comment

- 1283 SDI Heads for Fiscal Crash ■ With a Little Help ■ Army, Air Force Eye SDI Spinoffs ■ The Ups and Downs of Strategic Defense Weapons
1286 In Peru, Even Potato Research Is High Risk
1287 Gene Therapy Clears First Hurdle
1288 Greenpeace and Science: Oil and Water?
1290 Academy of Engineering Elects New Members

Research News

- 1291 Particle Physicists Look to the Heavens
1294 Heart Like a Wheel
1295 Tweaking Molecules with Laser Light
1296 CF Screening Delayed for a While, Possibly Forever
1297 Ozone Destruction Closer to Home
1298 *Briefings*: Prospectors Cash In on Geologist's Find ■ Transgenic Carp: Pond-Ready? ■ Technology Unlocks "Lost" Writings ■ Stanford Patents Pay

Articles

- 1299 Drug Prevention in Junior High: A Multi-Site Longitudinal Test:
P. L. ELLICKSON AND R. M. BELL
1306 Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions: J. U. BOWIE, J. F. REIDHAAR-OLSON, W. A. LIM, R. T. SAUER

Research Article

- 1311 Deep Magma Body Beneath the Summit and Rift Zones of Kilauea Volcano, Hawaii: P. T. DELANEY, R. S. FISKE, A. MIKLIUS, A. T. OKAMURA, M. K. SAKO

Reports

- 1317 Femtosecond Pulse Sequences Used for Optical Manipulation of Molecular Motion: A. M. WEINER, D. E. LEAIRD, G. P. WIEDERRECHT, K. A. NELSON

■ SCIENCE is published weekly on Friday, except the last week in December, and with a supplement in March by the American Association for the Advancement of Science, 1333 H Street, NW, Washington, DC 20005. Second-class Non-profit postage (publication No. 484460) paid at Washington, DC, and at an additional entry. Copyright © 1990 by the American Association for the Advancement of Science. The title SCIENCE is a registered trademark of the AAAS. Domestic individual membership and subscription (51 issues): \$75. Domestic institutional subscription (51 issues): \$120. Foreign postage extra: Canada \$46, other (surface mail) \$48, air mail via Amsterdam \$85. First class, airmail, school-year, and student rates on request. Single copy sales: Current issue, \$3.50; back issues, \$5.00; Biotechnology issue, \$6.00 (for postage and handling, add per copy \$0.50 U.S., \$1.00 all foreign); Guide to Biotechnology Products and Instruments, \$18 (for postage and handling add per copy \$1.00 U.S., \$1.50 Canada, \$2.00 other foreign). Bulk rates on request. Authorization to photocopy material for internal or personal use under circumstances not falling within the fair use provisions of the Copyright Act is granted by AAAS to libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of \$1 per copy plus \$0.10 per page is paid directly to CCC, 27 Congress Street, Salem, Massachusetts 01970. The identification code for SCIENCE is 0036-8075/83 \$1 + .10. Change of address: allow 6 weeks, giving old and new addresses and 11-digit account number. Postmaster: Send Form 3579 to SCIENCE, P.O. Box 1723, Riverton, NJ 08077. SCIENCE is indexed in the *Reader's Guide to Periodical Literature* and in several specialized indexes.

■ The American Association for the Advancement of Science was founded in 1848 and incorporated in 1874. Its objectives are to further the work of scientists, to facilitate cooperation among them, to foster scientific freedom and responsibility, to improve the effectiveness of science in the promotion of human welfare, to advance education in science, and to increase public understanding and appreciation of the importance and promise of the methods of science in human progress.



COVER Basalt lava erupted from Kilauea Volcano, Hawaii, pours 3 meters from a shallow tube into the Pacific Ocean. The current eruption began in January 1983; the lava produced now covers 70 square kilometers, including 150 acres of new land formed along the seacoast. Analysis of more than 20 years of ground deformation data suggests that Kilauea's magma system is deeper and more extensive than previously thought. See page 1311. [Photographed on 27 November 1989 by J. D. Griggs, U.S. Geological Survey]

- 1319 The Framework Topology of ZSM-18, a Novel Zeolite Containing Rings of Three (Si,Al)-O Species: S. L. LAWTON AND W. J. ROHRBAUGH
- 1322 Amazon Deforestation and Climate Change: J. SHUKLA, C. NOBRE, P. SELLERS
- 1325 Fossil Soils and Grasses of a Middle Miocene East African Grassland: G. J. RETALLACK, D. P. DUGAS, E. A. BESTLAND
- 1328 Requirement for Activin A and Transforming Growth Factor- β 1 Pro-Regions in Homodimer Assembly: A. M. GRAY AND A. J. MASON
- 1330 Imaging and Manipulating Molecules on a Zeolite Surface with an Atomic Force Microscope: A. L. WEISENHORN, J. E. MAC DOUGALL, S. A. C. GOULD, S. D. COX, W. S. WISE, J. MASSIE, P. MAIVALD, V. B. ELINGS *et al.*
- 1333 Molecular Cloning of the *Bombyx mori* Prothoracicotropic Hormone: A. KAWAKAMI, H. KATAOKA, T. OKA, A. MIZOGUCHI, M. KIMURA-KAWAKAMI, T. ADACHI, M. IWAMI, H. NAGASAWA, A. SUZUKI, H. ISHIZAKI
- 1335 Isolation of a cDNA from the Virus Responsible for Enterically Transmitted Non-A, Non-B Hepatitis: G. R. REYES, M. A. PURDY, J. P. KIM, K.-C. LUK, L. M. YOUNG, K. E. FRY, D. W. BRADLEY
- 1339 Calcium-Induced Movement of Troponin-I Relative to Actin in Skeletal Muscle Thin Filaments: T. TAO, B.-J. GONG, P. C. LEAVIS
- 1341 Hypoxic Dilation of Coronary Arteries Is Mediated by ATP-Sensitive Potassium Channels: J. DAUT, W. MAIER-RUDOLPH, N. VON BECKERATH, G. MEHRKE, K. GÜNTHER, L. GOEDEL-MEINEN
- 1344 Simulation of Paleocortex Performs Hierarchical Clustering: J. AMBROS-INGERSON, R. GRANGER, G. LYNCH

Book Reviews

- 1349 Economic Anthropology, reviewed by S. B. BRUSH ■ Complex Organismal Functions, R. WASSERSUG ■ Large Deviations, S. R. S. VARADHAN ■ Prediction of Protein Structure and the Principles of Protein Conformation, T. E. CREIGHTON ■ Books Received

Products & Materials

- 1354 Programmable Electrochemical Detector ■ Kit for Measuring Oncogene Proteins ■ Sequence Analysis Software ■ Ground-Water Modeling Software ■ Small Implantable Osmotic Pump ■ Monoclonal Antibodies ■ Literature

Board of Directors

Richard C. Atkinson
*Retiring President,
Chairman*
Donald N. Langenberg
President
Leon M. Lederman
President-elect

Mary Ellen Avery
Francisco J. Ayala
Eugene H. Cota-Robles
Robert A. Frosch
Joseph G. Gavin, Jr.
John H. Gibbons
Beatrice A. Hamburg
Florence P. Haseltine
William T. Golden
Treasurer
Richard S. Nicholson
Executive Officer

Editorial Board

Elizabeth E. Bailey
David Baltimore
William F. Brinkman
E. Margaret Burbidge
Pierre-Gilles de Gennes
Joseph L. Goldstein
Mary L. Good
F. Clark Howell
James D. Idol, Jr.
Leon Knapoff
Oliver E. Nelson
Yasutomi Nishizuka
Helen M. Ranney
David M. Raup
Howard A. Schneiderman
Larry L. Smarr
Robert M. Solow
James D. Watson

Board of Reviewing Editors

John Abelson
Don L. Anderson
Stephen J. Benkovic
Gunter K-J Blobel
Floyd E. Bloom
Henry R. Bourne
James J. Bull
Kathryn Calame
Charles R. Cantor
Ralph J. Ciccerone
John M. Coffin
Robert Dorfman
Bruce F. Eldridge
Paul T. Englund
Fredric S. Fay

Theodore H. Geballe

Roger I. M. Glass
Stephen P. Goff
Corey S. Goodman
Stephen J. Gould
Eric F. Johnson
Stephen M. Kosslyn
Konrad B. Krauskopf
Charles S. Levings III
Richard Losick
Joseph B. Martin
John C. McGliff
Anthony R. Means
Mortimer Mishkin
Roger A. Nicoll
Carl O. Pabo
Yeshayau Pocker

Dennis A. Powers

Erdi Ruoslahti
Thomas W. Schoener
Ronald H. Schwartz
Terrence J. Sejnowski
Robert T. N. Tjian
Virginia Trimble
Emil R. Unanue
Geerat J. Vermeij
Bert Vogelstein
Harold Weintraub
Irving L. Weissman
Zena Werb
George M. Whitesides
Owen N. Witte
William B. Wood

***** 5-DIGIT 94304
38 00001064898SC 04/27/90 M
JAMES HESLIN
TOWNSEND & TOWNSEND LIB
2ND FL
379 LYTTON AVE
PALO ALTO CA 94304